AUDITOR'S REPORT

on the financial statements of AO Ranbaxy for 2016



Тел: +7 495 797 56 65 Факс: +7 495 797 56 60 reception@bdo.ru www.bdo.ru АО «БДО Юникон» Россия, 117587, Москва, Варшавское шоссе, д. 125, стр. 1, секция 11

AUDITOR'S REPORT

To the shareholders of AO RANBAXY

Audited entity

Joint Stock Company RANBAXY (AO RANBAXY)

Reg. No. 1047796353846.

Location: Prospekt Mira 119, bld. 537/2, Moscow, 129223, Russia.

Auditor

BDO Unicon Aktsionernoe Obshchestvo (BDO Unicon AO)

Registered by Tax Inspectorate No. 26 of the RF Ministry of Taxation in the Southern Administrative District of the City of Moscow, Certificate of Registration No. 1037739271701.

Registered office: 11/1, 125 Warshavskoye Shosse, Moscow, 117587, Russian Federation.

BDO Unicon AO is a member of the professional audit association Self-regulated organization of auditors "Russian Union of auditors" (Association) (Main State Registration No. 11603059593 in the State Register of Auditors and Audit Organizations).

Authority to sign the Auditor's Report rests with Maxim Aksenov, Director, by way of Power of Attorney No. 12-01/2016-БДО of 1 January 2016.

We have audited the enclosed financial statements of AO Ranbaxy for 2016, which comprise:

- the balance sheet as at 31 December 2016;
- statement of income for the year ended 31 December 2016;
- supplements to the balance sheet and the statement of income, including:

statement of changes in equity for the year ended 31 December 2016;

the statement of cash flows for the year ended 31 December 2016;

explanatory notes to the financial statements for the year ended 31 December 2016.

Audited Entity's Responsibility for the Financial statements

Management of AO Ranbaxy is responsible for the preparation and fair presentation of these financial statements in accordance with legislation of the Russian Federation and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Federal Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involved performing audit procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The audit procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considered internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control.

An audit also included evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management of the audited entity, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient to provide a basis for our audit opinion.

Basis for Qualified Opinion

As a result of an incorrect recognition of the bonuses and awards, granted by the Company to buyers for achieving of certain volumes of regular purchases and early payment of goods, as other expenses, the lines "Revenue" and "Other expenses" of the income statement for 2016 are overestimated by 303,881 kRUR, the appropriate lines of the income statement for 2015 are overestimated by 201,519 kRUR, without any impact on tax calculations.

Qualified Opinion

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion paragraph, the financial statements present fairly, in all material respects, the financial position of AO Ranbaxy as at 31 December 2016 and its financial performance and cash flows for the year then ended in accordance with legislation of the Russian Federation.

BDO Unicon AO

M.N. Aksenov, Director

30 March 2017

Total number of pages bound: 59.



Balance Sheet

as at 31 December 2016			Codes
	OKUD form	C	710001
t i	Date (day, month, year)	31	12 2016
Entity Closed Joint Stock Company RANBAXY	OKPO 72983356		
Taxpayer identification number	INN	77	20508094
Type of economic activity Wholesaling of pharmaceutical and medical products	OKVED	51.46.1	
Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	OKOPF / OKFS	67	16
Measurement unit: thousand Rubles	OKEI		384

Location:

1

-

119 Prospekt Mira, bldg. 537/2, Moscow, 129223, Russia7/2

Notes	Item	Code	As at 31 December 2016	As at 31 December 2015	As at 31 December 201
	ASSETS				
	I. NON-CURRENT ASSETS	1110	7 000	1.010	
1.1	Research and development results	1120	7 233	1 318	2 92
	Intangible development assets	1130			
	Tangible development assets	1140		-	
2.1	Fixed assets	1150	19 125	32 687	36 50
4.1	Income yielding investments into tangible assets	11.50	19125	32 007	30 50
	ценности	1160		_	
	Financial investments	1170		-	
3.1.	Deferred tax assets	1180	16 202	8 087	650
0.11	Other non-current assets	1190			000
	Total for Section I	1100	42 560	42 092	45 94
	II. CURRENT ASSETS				
4.1	Inventories	1210		715 171	456 39
	including:				
	Materials	12101		31	
	Goods	12102		711 151	452 4
	Selling expenses	12103		3 989	38
				0.000	
	Input VAT	1220	55	525	3 5
6.6;	Accounts receivable	1230	2 172 551	1 712 356	1 395 90
	including:				
3.1.	Settlements with suppliers and contractors	12301		26 274	14 03
	Settlements with buyers and customers	12302		1 572 431	1 302 0
	Settlements on taxes and levies	12303		45 148	41 9
		12304			
	Settlements on social insurance and security	12304		4 862	2 9
	Settlements with accountable persons	12305		11 317	3 4
		12306			
	Other settlements with personnel	12000		5 805	2 54
		12307			
	Settlements with sundry debtors and creditors			46 519	28.8
3.1.		1240			
	Financial investments (excluding cash equivalents)	ļ	412 333	425 000	235 00
	including:	10101			
	Deposit accounts	12401		425 000	235 00
	Cash and cash equivalents	1250	144 221	141 548	43 78
	including:	1000			
	Cash on hand	12501		3	
	Operating accounts	12502		138 276	42 50
	Foreign currency accounts	12503		3 269	1 20
	Other current assets	1260	1 597	954	1 18
	Total for Section II	1200	3 582 478	2 995 554	2 135 78
	BALANCE	1600	3 625 038	3 037 646	2 181 72

Form 0710001 p.2

Notes	ltem	Code	As at 31 December 2016	As at 31 December 2015	As at 31 Decembe 2014
	LIABILITIES				
	III. CAPITAL AND RESERVES				
	Share capital (contributed capital, charter capital,				
5.	contributions of partners)	1310	163 000	163 000	3 00
	Treasury shares	1320			
	Revaluation of non-current assets	1340		1	
	Additional capital (without revaluation)	1350			
5.	Reserve capital	1360	750	750	75
5.	Retained earnings (uncovered loss)	1370	676 733	464 791	396 03
	Total for Section III	1300	840 483	628 541	399 78
	IV. LONG-TERM LIABILITIES Borrowings	1410			
-	including:	1410			
	Long-term loans	14101			
3.1.	Deferred tax liabilities	1420	5 402	5 272	4 60
0.11	Estimated liabilities	1430	0 402		
	Other liabilities	1450			
	Total for Section IV	1400	5 402	5 272	4 60
	V. CURRENT LIABILITIES				
3.1.	Borrowings	1510	431 788	508 213	387 28
	Accounts payable	1520	2 019 379	1 668 154	1 251 47
	including:				
3.1.	Settlements with suppliers and contractors	15201		1 627 497	1 049 59
	Settlements with buyers and customers	15202		375	45
	Settlements on taxes and levies	15203		9 163	10 51
	Settlements with sundry debtors and creditors	15204		31 119	32 51
	Settlements with founders related to	15205			
	contributions to charter capital	15205		-	158 40
	Deferred income	1530			
6.9.	Estimated liabilities	1540	327 987	227 466	138 58
	Other liabilities	1550		5	
	Total for Section V	1500	2 779 153	2 403 833	1 777 34
	BALANCE	1700	3 625 038	3 037 646	2 181 72

Head __________(signature)

Artur Valiev (full Name)

March 29, 2017

L

Profit and Loss Statement

1

for January - December 2016 Date Entity Closed Joint Stock Company RANBAXY Taxpayer identification number Type of economic activity Wholesaling of pharmaceutical and medical products Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership Measurement unit: thousand Rubles	Form under OKUD ite (day, month, year) OKPO INN OKVED OKOPF / OKFS OKEI	72983	002 12 2016 356 8094 5.1 16
Entity Closed Joint Stock Company RANBAXY Taxpayer identification number Type of economic activity Wholesaling of pharmaceutical and medical products Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	ite (day, month, year) OKPO INN OKVED OKOPF / OKFS OKEI	31 729833 7720504 51.46 67	12 2016 356 8094 5.1 16
Entity Closed Joint Stock Company RANBAXY Faxpayer identification number Fype of economic activity Wholesaling of pharmaceutical and medical products Drganizational legal form / form of ownership Closed Joint Stock Company / Private ownership	OKPO INN OKVED OKOPF / OKFS OKEI	729833 7720504 51.46 67	356 8094 5.1 16
Taxpayer identification number Type of economic ctivity Wholesaling of pharmaceutical and medical products Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	INN OKVED OKOPF / OKFS OKEI	7720500 51.46 67	8094 5.1 16
axpayer identification number ype of economic ctivity Wholesaling of pharmaceutical and medical products Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	OKVED OKOPF / OKFS OKEI	51.46 67	5.1
ype of economic ctivity Wholesaling of pharmaceutical and medical products Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	OKVED OKOPF / OKFS OKEI	51.46 67	5.1
Wholesaling of pharmaceutical and medical products organizational legal form / form of ownership closed Joint Stock Company / Private ownership	OKOPF / OKFS OKEI	67	16
Organizational legal form / form of ownership Closed Joint Stock Company / Private ownership	OKEI		
Closed Joint Stock Company / Private ownership	OKEI		
teasurement unit: thousand Rubles	1	384	ļ
	1		
Notes Items Code J	January - December 2016	January - Dece	ember 201
3.1. Revenue 2110	4 996 365		3 630 73
6.7 Cost of sales 2120	(3 065 092)		(2 236 74
Gross profit (loss) 2100	1 931 273		1 393 9
3.1. Business expenses 2210	(1 385 383)		(999 59
Management expenses 2220			
3.1. Profit (loss) on sales 2200	545 890		394 39
Income from participation in other entities 2310			
3.1. Interest receivable 2320	33 763		24 5
3.1 Interest payable 2330	(15 439)		(12 74
Other income 2340	416 054		306 5
Other expenses 2350	(681 947)		(600 29
Profit (loss) before taxes 2300	298 321	-	112 4
Current income tax 2410	(94 363)		(44 59
including permanent tax liabilities (assets) 2421 (активы)	(26 713)		21 19
Change in deferred tax liabilities 2430	(129)		(66
Change in deferred tax assets 2450	8 115		1 57
Other 2460	(1)		(
including: Fines and penalties for violation of tax and other legislation 24601			(
Net profit (loss) 2400	211 943		68 70

Form 0710002 c.2

Notes	Item	Code	January - December 2016	January - December 2015
	Revaluation of non-current assets not included in net profit (loss) for the period	2510	-	
	Result of other operations not included in net profit (loss) for the period	2520	-	
	Total financial result for the period	2500	211 943	68 760
	FOR REFERENCE ONLY			
	Basic earnings (loss) per share	2900	1,3	0,42
	Diluted earnings (loss) per share	2910	1,3	0,42

Head _______(signature)

Artur Valiev (full Name)

March 29, 2017

L

L

ł

Statement of Cash Flows for January - December 2016

[

uity
) Eq
es in
ang
<u>ה</u>
-

			. Changes in Equity	۲ <mark>ر</mark>			
Item	Code	Share capital	Treasury shares	Additional Capital	Reserve capital	Retained earnings (uncovered loss)	Total
Equity as at 31 December 2014	3100	3 000	-		750	396 031	399 781
<u>For 2015</u> Total increase in equity:	3210					ER 760	60 760
including:						2	200
net profit	3211	×	×	×	×	68 760	020 02
revaluation of assets	3212	×	×		: ×	202	00 / 00
gains taken directly to equity	3213	×	×		: >		
additional issue of shares	3214	160 000			- <	- >	160,000
increase in par value of shares	3215					<	
reorganization of the legal entity	3216		-				<

				*		1410 - U	Form 0710023 p.2
Item	Code	Share capital	Treasury shares	Additional Capital	Reserve capital	Retained earnings (uncovered loss)	Total
Total decrease in equity:	3220	•	-				
including: loss	3221	Х	>	>	>		
revaluation of assets	3222	<	< ×	<	< >		
expenses directly charged to equity	0000	. ,	: >		< ;		
reduction in par value of charge	2220	<	×		×		
reduction in number of shares	3224		-		××		
reorganization of the legal entity	0000				×		
dividends	3227	×	×		>		
Change in additional capital	3230	×		<	<		>
Change in reserve capital	3240	×	×	×			<>
Equity as at 31 December 2015	3200	163 000			750	464 701	600 E41
For 2016					3		1+0 020
I OTAL INCREASE IN EQUITY:	3310					211 943	211 943
including: net profit	3311	×	~	~	>		
revaluation of assets	3312	×	×	<	< ×	211343	211 943
-							
gains taken directly to capital	3313	×	×	-	×		
additional issue of shares	3314				×	×	
increase in par value of shares	3315		-		×		×
reorganization of the legal entity	3316						
Total decrease in equity:	3320		-				
including: loss	3321	×	×	>	>		
revaluation of assets	3322	×	×	<	<		
expenses directly charged to equity	0000	>	;				
reduction in part value of shares	3324	<	<				
reduction in number of shares	3325				< >		
reorganization of the legal entity	3326						
dividends	3327	×	×	×	×		
Change in additional capital	3330	×	×				×
Change in reserve capital	3340	×	×	×			×
Equity as at 31 December 2016	1 3300 1	163 000	•		750	676 733	840 483

Form 0710023 p.3

Item					
Item		As at 31 December	Changes in e	Changes in equity in 2015	Ac of Of December
	Code	2014	due to net profit (loss)	due to other factors	2015
Total capital					
before adjustments	3400	399 781	68 760	160 000	628 541
adjustments arising from					
changes in accounting policies	3410		•	•	
correction of errors	3420			•	
after adjustments	3500	182 666	68 760	160 000	628 541
including:					
retained earnings (uncovered loss):					
before adjustments	3401	396 031	68 760	•	464 791
adjustments arising from:					
changes in accounting policies	3411	ł		Ŀ	
correction of errors	3421	-	•	J	
after adjustments	3501	396 031	68 760	3	464 791
before adjustments	3402				
adiustments arising from:					-
changes in accounting policies	3412				
correction of errors	3422				
after adjustments	3502				

0

Form 0710023 p.4

(

			3. Net assets	
Item	Code	As at 31 December 2016	As at 31 December 2015	As at 31 December 2014
Net assets	3600	840 483	628 541	399 781

Head Artur Valiev (signature) (full Name)

March 29, 2017

Calculation of the Net Asset Value

Closed Joint Stock Company Ranbaxy (name of the organization)

 0,	 organizationy	

	Balance sheet			
Item	line code	As at December 31, 2016	As at December 31, 2015	As at December 31, 201
Assets	•			
Intangible assets	1110	7 233	1 318	2 92
Results of research and development			1010	2.52
	1120		-	
Intangible development assets	1130	-		
Tangible development assets	1140	-		
Fixed assets	1150	19 125	32 687	00.50
Income-bearing investments into		10 120	32 007	36 50
tangible assets	1160			
Financial investments (long-term)				
(3	1170			
Deferred tax assets	1180	16 202		
Other non-current assets	1190	10 202	8 087	6 50
Inventories	1210	054 704	•	
	1210	851 721	715 172	456 39
Input value added tax	1220	55	525	0.50
Receivables*	1230	2 172 551	1 712 356	3 53
Financial investments		2172 001	1712 330	1 395 90
(short-term)	1240	412 333	425 000	005.00
Cash and cash		412 000	425 000	235 00
equivalents	1250	144 221	141 547	40.70
Other current assets	1260	1 597	954	43 78
TOTAL ASSETS	-	3 625 038	3 037 646	1 18
Liabilities		5 025 038	3 037 646	2 181 72
Borrowings		<u>г – – – т</u>		
(long-term)	1410			
Deferred tax	1410			
liabilities	1420	5 402	C 070	
Estimated liabilities	1420	5 402	5 272	4 60
(long-term)	1430			
Other liabilities	1400	-		
(long-term)	1450			
Borrowings				
(short-term)	1510	431 788	500.010	
Accounts payable	1520	2 019 379	508 213	387 28
Estimated liabilities	1020	20193/9	1 668 154	1 251 47
(short-term)	1540	327 987	007 40-	
Other liabilities	1040	327 987	227 466	138 58
(short-term)	1550			
Total liabilities	- 1000	2 784 555	-	
Net asset value			2 409 106	1 781 947
	•	840 483	628 540	399 78

* Excluding the outstanding contributions to the authorized capital from members (founders).

L

Statement of Cash Flows

for January - December 2	016	_	Codes
		Form under Ok	
		Date (day, month, y	rear) <u>31 12 2016</u>
Entity Closed Joint Stock Company RANBAXY		0	(PO 72983356
Taxpayer identification number			INN 7720508094
Type of economic activity <u>Wholesaling of pharmaceutical and medical</u>	products	OK'	51.46.1
Organizational legal form / form of ownership			67 16
Closed Joint Stock Company / Private ownership Measurement unit: thousand Rubles	_	OKOPF / O	KFS
Measurement unit. Inousano Rubies		C	0KEI384
Item	Code	January - December 2016	January - December 2015
Cash flows from operating activities		2010	
Total receipts	4110	4 474 352	3 305 903
including:			
sales of products, goods, works and services	4111	4 423 867	3 237 769
lease payments, license fees, royalties, commissions, fees	3		
and	4112		-
resale of investments	4113		-
	4114		-
other receipts	4119	50 485	68 134
Total payments	4120		(3 032 676)
including: to suppliers (contractors) for materials, supplies, works			
and services	4121		(2 096 572)
employee compensation	4122		(487 438)
interest on debt obligations	4123		(6 606)
corporate income tax	4124	(152 628)	(101 114)
	4125		-
other payments	4129	(540 978)	(340 946)
Net cash flow from operating activities	4100	(161 839)	
Cash flows from investing activities			
Total receipts	4210	176 801	(163 040)
including			
sales of non-current assets (excluding financial			
investments)	4211	3 409	2 950
sale of other shares (interests) in other entities	4212		-
loans repayments, sale of debt securities (monetary claims			
against other persons) dividends, interest on financial debt investments and	4213	150 000	(190 000)
similar receipts from equity participation in other			
organizations			
organizations	4214	23 392	24 010
other receipts	4215		-
	4219		-
Total payments	4220	(11 836)	(15 742)
including:			
acquisition, creation, modernization, reconstruction and			
preparation of non-current assets for use	4221	(10.900)	(10,700)
	7221	(10 802)	(13/92)
acquisition of shares (interests) in other entities	4222		
acquisition of debt securities (monetary claims against			
other persons), disbursement of loans	4223		
acquisition of debt securities (monetary claims against			
other persons), disbursement of loans acquisition of debt	4224		
	4225		
other payments	4229	(1 034)	1.050)
Net cash flow from investing activities	4200	164 965 (
		104 905	110 102

Form 0710004 p.2

			Form 07 10004 p.2
Item	Code	January - December 2016	January - December 2015
Cash flows from financing activities		- Ser S	
Total receipts	4310		1 600
including:			
credit and loan proceeds	4311		-
cash deposits of owners (members)	4312		
issue of shares, increase in participatory interests	4313		1 600
issue of bonds, bills and other debt securities, etc.	4314		
	4315		-
other receipts	4319		_
Total payments	4320		
including to owners (members) in connection with repurchase of shares (interests) from them or termination or their participation	4321		
payment of dividends and other profit distributions to	4021		
owners (members)	4322		-
in connection with redemption (repurchase) of bills and other debt securities, credit and loan repayments	4323		-
	4324		-
other payments	4329		-
Financial operations cash flow balance	4300		1 600
Net cash flow for the reporting period	4400	3 126	96 045
Net cash flow for the reporting period Balance of cash and cash equivalents as at beginning of			
the reporting period	4450	141 548	43 782
Balance of cash and cash equivalents as at end of the reporting period	4500	144 221	141 548
Effect of changes in foreign exchange rates against the ruble	4490	(453)	1 721

Head _____

-

Artur Valiev (full Name)

-

March 29, 2017

(signature)

Notes

to the accounting (financial) statements of AO Ranbaxy for 2016.

1. Information about the Company

1.1. Full name of the Company: Joint Stock Company "Ranbaxy"

1.2. Registered address: 119 Prospekt Mira, bldg. 537/2, Moscow, 129223, Russian Federation

1.3. Actual address: 119 Prospekt Mira, bldg. 537/2, Moscow, 129223, Russian Federation

1.4. Date of state registration: May 20, 2004; Primary State Registration Number: 1047796353846.

1.5. Authorized capital of the Company makes up 163,000,000 rubles. Shareholder structure: Ranbaxy (Netherlands) B.V., registered with the Chamber of Commerce and Industry of Amsterdam under No. 33254757: 99 percent of the authorized capital; Ranbaxy Holdings (UK) Ltd., registered at Company House of England and Wales under No. 3062051: 1 percent of the authorized capital. Shares in the authorized capital are fully paid. Quantity of placed securities: 163,000. The par value of each security is 1,000 rubles.

The ultimate beneficiary of the company is Sun Pharmaceutical Industries Limited, which is based in Mumbai, India. Sun Pharmaceutical Industries Limited is traded on Bombay Stock Exchange (BSE Limited) and National Stock Exchange of India Limited. Sun Pharmaceutical Industries is one of the world's largest manufacturers and retailers of pharmaceutical products.

1.6. The Company has no subsidiaries or affiliates.

1.7. Information about standalone subdivisions.

On December 19, 2008, a standalone subdivision "Warehouse for wholesaling medicinal products" was established and registered at its location (address: 2, let. B, B2 Dachnaya Street, Village of Davydovskoye, Luchinskoye Rural Settlement, Istra District, Moscow Region, 143521, Russian Federation) with Inspectorate of the Federal Tax Service of Russia for the town of Istra, Moscow Region.

On April 14, 2014, the location of the subdivision was changed (new address: 244 Village of Leshkovo, Istra District, Moscow Region, Russian Federation).

- On May 7, 2009, a standalone subdivision was established and registered at its location (address:
 12 B Tambovskaya Street, St. Petersburg, 192007, Russian Federation) with Interdistrict Inspectorate of the Federal Tax Service of Russia No. 27 in St. Petersburg.
- On September 15, 2009, a standalone subdivision was established and registered at its location (address: 44/17 Dekabristov Street, Yekaterinburg, Sverdlovsk Region, 620142, Russian Federation) with Inspectorate of the Federal Tax Service of Russia for Leninsky District of Yekaterinburg.

- On September 15, 2009, a standalone subdivision was established and registered at its location (address: 104/32 Pushkinskaya Street, office No. 9, Rostov-on-Don, Rostov Region, 344006, Russian Federation) with Interdistrict Inspectorate of the Federal Tax Service of Russia No. 25 in Rostov Region.
- On April 29, 2014, a standalone subdivision was established and registered at its location (address: 1 Uritskogo Street, Suite No. 2, Samara, Samara Region, 443030, Russian Federation) with Inspectorate of the Federal Tax Service of Russia in Zheleznodorozhny District of Samara.
- On April 29, 2014, a standalone subdivision was established and registered at its location (address: 45 Dekabristov Street, Omsk, Omsk Region, 644024, Russian Federation) with Inspectorate of the Federal Tax Service of Russia No. 2 in Central Administrative District of Omsk.
- On April 29, 2014, a standalone subdivision was established and registered at its location (address: 111 Uritskogo Street, Suite No. 3, Krasnoyarsk, Krasnoyarsk Territory, 660049, Russian Federation) with Inspectorate of the Federal Tax Service in Central District of Krasnoyarsk.

1.8. The main business activity of the Company is wholesaling of pharmaceutical products. License (current): FS-99-02-003803 issued on April 14, 2014. Location covered by license FS-99-02-003803: 244 Village of Leshkovo, Istra Iistrict, Moscow Region, Russian Federation.

1.9. The Company is subject to mandatory audit in accordance with the criteria set forth in Federal Law No. 307-FZ "On Auditing Activity" dated December 31, 2008, which was entrusted to BDO Unicon AO. *1.10. Members of the Company's executive and control bodies:*

- 1. General Director: Arthur Valiev;
- 2. Financial Director: Vivek Kapur;
- 3. Chief Accountant: Ludmila Alekseevna Manuilova

2. Significant Accounting Policies.

2.1. Accounting policy for bookkeeping purposes.

The Company's accounting records are maintained in accordance with the accounting legislation of the Russian Federation. The Company's accounting statements have been prepared on the basis of the current accounting and reporting rules of the Russian Federation.

2.1.1. Accounting is done by the Company's Accounting Department, which is a separate structural subdivision headed by the Chief Accountant.

2.1.2. In accounting, income is determined in accordance with the Accounting Regulations "Income of Organizations" PBU 9/99 approved by Order of the Russian Ministry of Finance No. 32n. dated May 6, 1999. Sales are recorded in the accounts as follows:

- ordinary income is recorded in account 90.1.1 "Sales" when the products are shipped (transferred to the buyer) and payment documents for the shipped goods are passed to the buyer, taking

into account the time of transfer of ownership. Ordinary income is income from activities that generate revenues accounting for more than 5 percent of total sales;

- remuneration under commission, engagement and agency agreements is recorded when the report of the commission agent (nominee, agent) on sales of goods, works and services is approved by the principal.

Sales proceeds derived from activities that are subject to value added tax at different rates or are exempt from value added tax are recorded in subaccounts of account 90.1.1 "Sales".

2.1.3. In accounting, expenses are determined in accordance with the Accounting Regulations "Expenses of Organizations" PBU 10/99. Expenses are recorded in the accounting records regardless of whether there is an intention to generate revenue or other income and the form of expenses (cash, in kind, or other). Expenses are recognized in the reporting period in which they were incurred, irrespective of when cash is paid.

2.1.4. Useful lives of fixed assets are determined based on the Classification of fixed assets included in depreciation groups approved by Resolution of the Russian Government No. 1 dated January 1, 2002. For new fixed assets the following depreciation periods are established:

Furniture	61 months
Office equipment	37 months
Computer equipment	35 months
Motor vehicles	60 months

2.1.5. Fixed assets are depreciated using the straight-line method.

2.1.6. Low-value fixed assets with a cost not exceeding 40,000 rubles, as well as books, brochures and other publications are expensed as they are released for use.

2.1.7. Annual revaluation of fixed assets is not performed.

2.1.8. Deferred expenses posted to account 97 are classified in the accounting statements as follows: as advances made:

- insurance expenses;
- passes;
- advertising.

as other current assets:

- licensing expenses;
- expenses on purchase of computer software and databases;
- certification expenses;
- fixed assets repair expenses;
- expenses on customs services;
- permits to employ foreign nationals.

2.1.9. Goods and materials are written off on FIFO basis.

2.1.10. Provisions for doubtful debts are made with due regard for expediency and in accordance with the accounting regulations.

2.1.11. A provision for impairment of inventories is made at the end of the year taking into account the remaining shelf life. The amount of the provision is calculated on a monthly basis. Stock balance is determined at the end of the quarter and written down to market value. For goods with a remaining shelf life of no more than 6 months, the provision is made at 100 percent; for goods with a remaining shelf life of no less than 7 months but no more than 12 months, at 50 percent; and for goods with a remaining shelf life of no more than 50 percent and no less than 13 months as on the date the provision is recorded, at 25 percent. In addition, goods are measured on other factors in accordance with PBU 5/01.

2.1.12. The Company makes provisions for estimated liabilities in accordance with PBU 8/2010.

2.1.13. The Company applies PBU 18/02. Accrual ledgers are created using 1C: Manufacturing Enterprise Management.

2.1.14. In accordance with the prescribed marketing policy, buyers benefit from awards (bonuses) and discounts.

2.1.15. Short-term deposits with banks for up to 3 months are reported in the accounting statements as financial investments.

2.2. Accounting policy for tax purposes.

2.2.1. The Company determines its VAT tax base as products are shipped.

2.2.2. The Company uses the accrual method of income and expense recognition when calculating corporate income tax.

2.2.3. Purchased goods whose costs are deducted from sales proceeds are valued using the FIFO method. Materials are written off on FIFO basis.

2.2.4. Useful lives of fixed assets are determined based of the Classification of fixed assets included in depreciation groups approved by Resolution of the Russian Government No. 1 dated January 1, 2002. The period of use of acquired second-hand fixed assets is determined taking into account the period of actual use by the previous owners.

2.2.5. Depreciable assets are depreciated using the straight-line method.

2.2.6. Depreciable assets include assets with an original cost of more than RUB 100 000 and a useful life of more than 12 months. Assets with a cost of less than RUB 100 000 are recorded within material expenses and are expensed in the manner prescribed for indirect costs (as a lump sum). Low-value assets written off are kept off-balance sheet until they are actually disposed of.

2.2.7. The Company creates a provision for vacation pay, a provision for payment of bonuses to employees based on annual performance, and a provision for doubtful debts for tax purposes.

2.2.8. The Company creates tax accounting ledgers using specialized accounting software 1C: Manufacturing Enterprise Management.

3. Financial and Economic Activities of the Company.

3.1. Description of the Company's activities during the reporting year.

3.1.1. In 2016, revenues from sales of goods within operating activities totaled RUB 4.996.365 thousand (excluding VAT), which makes up 99.93 percent of total sales; other income from sales of fixed assets amounted to RUB 3 435 thousand (excluding VAT), which accounts for 0,07 percent of total sales. Gross operating profit was RUB

1 931 273 thousand.

In 2015, revenues from sales of goods within operating activities totaled RUB 3 630 734 thousand (excluding VAT); gross operating profit amounted to RUB 1 393 986 thousand.

The Company does not carry out any other types of activities.

3.1.2. In 2016, the Company generated RUB 545 890 thousand in profit from sales versus RUB 394 394 thousand in 2015 (up 39 percent).

The growth in profit is attributable to the following factors:

- an increase in revenues by RUB 1 365 631 thousand (or 37.6 percent);

- a decrease in the share of production cost in relation to revenue by 0,27 percent (61,34 percent in 2016 and 61,61 percent in 2015).

3.1.3. The structure of business expenses is as follows:

Structure of business expenses

	2016	2015	Change
Payroll and provisions	647 899	519 138	128 761
Allocations to funds	118 705	96 490	22 215
Advertising	211 558	107 165	104 393
Marketing	35 617	23 765	11 852
Processing of goods	40 468	35 567	4 901
Certification	11 803	9 664	2 139
Maintenance and repair of motor vehicles	50 582	33 246	17 336
Car lease	38 482	32 680	5 802
Insurance	39 142	30 720	8 422
Lease	22 540	15 402	7 138
Depreciation	18 325	22 392	(4 066)
Travel expenses	42 483	25 842	16 641
Hospitality expenses	1 516	2 675	(1 159)
Audit	3 949	3 632	317
Software products	6 1 1 9	5 418	701
Other material costs	7 342	11 967	(4 625)
Other expenses	88 852	23 829	65 023
Total	1 385 383	999 592	385 791

Payroll and provisions account for the largest share of the Company's business expenses (46,77 percent), with advertising expenses being another major contributor (15,27 percent); compared to the previous year, payroll increased while advertising expenses slightly decreased. Advertising was conducted via TV, radio, and public transport.

The Company increased its staffing in 2016. The average number of employees in 2016 was 464 versus 429 in 2015, representing a 8,16 percent increase (by 35 persons).

3.1.4. The Company's accounts receivable from customers and buyers as at December 31, 2016 amounted to RUB 1 899 300 thousand.

	At the beginning of the period	Creation of provision	Use of provision	Reversal of provision	At the end of the period
2016	46 063	22 592	(29 935)	(30 225)	8 495
2015	37 891	46 063	0	(37 891)	46 063

Provision for doubtful receivables from customers and buyers, RUB'000

At the end of 2016, Company created a provision for doubtful debts for the following organizations: - for accounts receivable from buyers:

- BCC LLC in the amount of RUB 15 878,02 (Fifteen thousand, eight hundred seventy-eight & 02/100 rubles).
- VTF LLC in the amount of RUB 487 366,67 (Seven hundred eighty-seven thousand, three hundred sixty six & 67/100 rubles).
- ZAO Genesis in the amount of RUB 7,764,525.34 (seven million, seven hundred sixty-four thousand, five hundred twenty-five and 34/100 rubles).
- Regional State Unitary Enterprise "Primorsk Regional Pharmacy" in the amount of RUB 191,840.47 (one hundred ninety-one thousand, eight hundred forty and 47/100 rubles).
- Pharm-Trede LLC in the amount of RUB 34 956,53 (Thirty four thousand, nine hundred and fifty six & 53/100 rubles)

The Company was the plaintiff (applicant) in the following legal proceedings:

Shreya Corporational CJSC in the amount of RUB 29 934 968,35 (Twenty nine million, nine hundred and thirty four thousand, nine hundred and sixty eight & 35/100 rubles)

In 2012, in the proceedings in the Arbitration Court of Moscow against Shreya Corporational (Closed Joint Stock Company) regarding entering the Company in the register of creditors. Claims of AO Ranbaxy were included in the register of creditors in accordance with the Ruling of the Arbitration Court of Moscow dated February 13, 2012 in case No. A40-57173/1073-296 "B".

In 2012, in the proceedings in the Arbitration Court of St. Petersburg and Leningrad Region against ZAO Genesis. The proceedings are completed, a settlement agreement has been approved, according to which AO "Ranbaxy" will receive RUB 7,764,525.34 from ZAO Genesis during the period from 2022 to 2026 (Ruling of the Arbitration Court of St. Petersburg and Leningrad Region dated February 21, 2012 in case No. A56-55543/2008). The ruling has entered into force.

On October 2, 2013, the Arbitration Court of Primorsk Territory issued a ruling in case No. A51-9651/2013 to include the claims of AO Ranbaxy in the amount of RUB 219,341.27 in the register of creditors of Regional State Unitary Enterprise "Primorsk Regional Pharmacy" as a third-priority creditor. The bankruptcy proceedings will last until June 13, 2016. Provision for doubtful receivables from suppliers (advances made), RUB'000

	At the				
	beginning of	Creation of		Reversal of	At the end of
	the period	provision	Use of provision	provision	the period
2016	1 048		-	-	1 048
2015	1 048	-	-	-	1 048

- for accounts receivable from suppliers:

• ZAO TK Novatorrus-Invest in the amount of RUB 1,048,078.94 (one million, forty-eight thousand, seventy-eight and 94/100 rubles).

On November 28, 2014, the Arbitration Court of Moscow issued a decision to recover the debt from ZAO TK Novatorrus-Invest in favor of AO Ranbaxy. Currently, the recovery is not possible due to insolvency of ZAO TK Novatorrus-Invest and the transfer of control to the liquidation commission. However, on January 23, 2015 TK ZAO Novatorrus-Invest was declared insolvent (bankrupt) by the Arbitration Court of Moscow. The claims of AO Ranbaxy in the amount of RUB 1,048,078.94 have been included in the register of creditors (ruling dated May 18, 2015 in case No. A40-175755/2014). The bankruptcy proceedings will last until July 31, 2017.

The total provision for losses at the end of 2016 for accounting and tax purposes amounts to RUB 8 495 thousand. The provision made at the end of 2016 for accounting purposes amounts to RUB 1,048 thousand.

The Company's accounts payable to suppliers and contractors as at December 31, 2016 totaled RUB 1 968 636 thousand. Accounts payable to suppliers increased significantly, by 20,96 percent (to RUB 341 131 thousand) compared to the previous year (in 2015, they amounted to RUB 1 627 505 thousand). The most increase was in payables to main suppliers of pharmaceutical products due to an increase in purchases of goods at the end of the year. The merchandise stock as at December 31, 2016 was RUB 845 194 thousand against RUB 711 151 thousand as at December 31, 2015 (up 18,84 percent).

The key suppliers of AO Ranbaxy in 2015 were SUN PHARMACEUTICAL INDUSTRIES LTD (formerly Ranbaxy Laboratories Limited (India) (takeover), Ranbaxy Therapy (Romania) and Sun Pharmaceutical Industries Ltd, with accounts payable to SUN PHARMACEUTICAL INDUSTRIES LTD (India) amounting to RUB 1 502 590 thousand (76,33 percent of total payables), to Ranbaxy Therapy – to RUB 460 673 thousand (23,40 percent of total payables), and to Sun Pharmaceutical Industries Ltd – no payable.).

3.1.5 In 2016, the Company paid interest of RUB 5 790 thousand on a short-term loan received in 2009 from Ranbaxy (Netherlands) and a long-term loan received in 2013 from Ranbaxy (Netherlands).

3.1.6. In 2016, the Company placed funds in short-term bank deposits. Total income from deposits amounted to RUB 20 265 thousand.

Interest accrued on bank balances amounted to RUB 13 497 thousand.

At the end of 2016, the funds placed on short-term deposits with OAO Sberbank amounted to RUB 275 000 thousand with the maturity dates in January 2017.

3.1.7. Other income and expenses of the Company recorded in lines 2340 and 2350 of the Profit and Loss Statement for 2016 were as follows:

Description	Other income (RUB'000)	Other expenses (RUB'000)
Exchange differences	152 182	(64 410)
Provision for impairment of inventory	227 616	(286 023)
Provision for doubtful debts	30 225	(22 592)
Provision for returned goods	208	(482)
Destruction of pharmaceutical products		(173)
Awards to suppliers		(110)
Bonuses to buyers		(303 881)
Insurance indemnity / expenses for insured events	1 872	(200 001)
Write-off of accounts receivable / payable		
Sales and write-offs of fixed assets	3 435	(756)
Taxes		(294)
Bank services		(1 053)
VAT expensed		(1000)
Other	516	(2 282)
Total	416 054	(681 947)

Other income and expenses of the Company recorded in lines 2340 and 2350 of the Profit and Loss Statement for 2015 were as follows:

Description	Other income (RUB'000)	Other expenses (RUB'000)
Exchange differences	138 128	(253 860)
Provision for impairment of inventory	83 087	(91 418)
Provision for doubtful debts	37 891	(46 063)
Provision for returned goods	357	(149)
Destruction of pharmaceutical products		(3 897)
Awards to suppliers	42 220	(00)1)
Bonuses to buyers		(201 519)
Insurance indemnity / expenses for insured events	774	(19)
Write-off of accounts receivable / payable		(120)
Sales and write-offs of fixed assets	3 059	(479)
Taxes		(505)
Write-off VAT on expenses		(987)
Bank services		(402)
Other	1 027	(875)
Total	306 543	(600 293)

3.1.8. According to the accounting data, in 2016 the Company earned a profit before tax of RUB 298 321 thousand; according to the tax accounting data, the Company received a profit of RUB 471 814 thousand. Provisional income tax expense amounted to RUB 59 664 thousand.

The permanent differences totaled RUB 133 564 thousand in 2016, resulting in a permanent tax liability of RUB 26 713 thousand. The bulk of this amount consisted of non-deductible expenses: the provision for impairment of goods amounted to RUB 58 407 thousand, medical insurance of employees' family members amounted to RUB 17 364 thousand, maintenance of vehicles amounted to RUB 5 383 thousand, employees training amounted to RUB 9 425 thousand, staff nutrition amounted to RUB 1,935 thousand, estimated liabilities (including vacation reserves, staff bonuses & bounties and other forthcoming payments) amounted to RUB 32 805 thousand, other expenses, excluding in tax accounting amounted to RUB 8,245 thousand.

Deferred tax assets in 2016 amounted to RUB 8 115 thousand. This amount basically composed by time deductible difference on bounties and retro bonuses granted to customers, increasing the accounting of estimated liabilities. Relevant expenses will be fixed in the period of registration of purchase orders on bonuses in tax accounting

Deferred tax liabilities increased to RUB 129 thousand in 2016. A significant portion of deferred liabilities is comprised of the difference due to the fact that in accounting the customs duties and taxes are included in the cost of goods, while in tax accounting they are expensed as a lump sum amount.

In 2015, the Company got a profit before tax of RUB 112 451 thousand according to accounting records. According to tax accounting records, the Company received a profit of RUB 223 001 thousand. Provisional income tax expense amounted to RUB 22 490 thousand.

The permanent differences in 2015 totaled RUB 105 995 thousand, giving rise to a permanent tax liability of RUB 21 199 thousand. This amount was mainly comprised of non-deductible expenses: the provision for impairment of goods and medical insurance of employees' family members amounted to RUB 10 254 thousand, maintenance vehicles amounted to RUB 3 833 thousand, estimated liabilities (including vacation reserves, staff bonuses & bounties and other forthcoming payments) amounted to RUB 88 885 thousand, other expenses, excluding in tax accounting amounted to RUB 3,023 thousand.

Increasing of Deferred tax assets in 2015 amounted to RUB 1 578 thousand. This amount mainly consisted of temporary difference on amortization of intangible assets

In 2015, deferred tax liabilities amounted to RUB 668 thousand. A significant portion of deferred liabilities is comprised of the difference due to the fact that in accounting the customs duties and taxes are included in the cost of goods, while in tax accounting they are expensed as a lump sum amount.

3.1.9. The Company has not issued any guarantees to third parties.

4. Social Indicators

Ite			
m No	Tu di sedere	2017	2015
No.	Indicator	2016	2015
1	Average number of employees	464	429

	Accrued wages, compensation payments and provisions for vacation pay and payment of year end bonuses, RUB		
2	thousand	647 899	519 138
3	Amount of accrued contributions, RUB thousand	118 705	96 490

5. Information about the Company's Equity (RUB'000)

Item No.	Indicator	2016	2015
1	Authorized capital	163 000	163 000
2	Reserve capital	750	750
3	Retained earnings	676 733	464 791

The Company has not paid any dividends and has not repurchased shares.

6. Reference Data

6.1. Calculation of the Company's net assets (RUB'000)

	Item	Balance sheet line code	At the beginning of the reporting period	At the end of the reporting period
	Assets			
1.	Intangible assets	1,110	1 318	7 233
2.	Fixed assets	1,150	32 687	19 125
3.	Other non-current assets	1,190	-	-
4.	Income-bearing investments into tangible assets	1,160	-	-
5.	Long-term and short-term financial investments	1170+1240	425 000	412 333
		1120+1130+1		
6.	Other non-current assets	140+1180	8 087	16 202
7.	Inventories	1,210	715 172	851 721
8.	Input VAT	1,220	525	55
9.	Accounts receivable	1,230	1 712 356	2 172 551
	Cash	1,250	141 547	144 221
11.	Other current assets	1,260	954	1 597
	Total assets taken into account in the calculation (sum of items 1-11) Liabilities		3 037 646	3 625 038
13.	Long-term liabilities under loans and credits	1,410	0	
14.	Other long-term liabilities	1420+1450	5 272	0 5 402
15.	Short-term liabilities under loans and credits	1.510	508 213	431 788
16.	Accounts payable	1,520	1 668 154	2 019 379
17.	Estimated liabilities	1,540	227 466	327 987
18.	Other current liabilities	1,510	421 400	521 701
19.	Total liabilities taken into account in the calculation (sum of items 13-19)		2 409 106	2 784 555

As at December 31, 2016, AO Ranbaxy did not have its own premises.

6.2. Information on the leased premises.

As at December 31, 2016, AO Ranbaxy did not have its own premises.

In 2016, lease contracts with the following organizations were in effect:

• OOO SP Tekhnopark (Moscow office).

Contract dated September 7, 2015 (unnumbered) for 569.70 square meters. Supplementary Agreement dated November 26, 2015 for 1,231 90 square meters (monthly rent for 1,231.90 square meters: RUB 1,438,015.31, including VAT). The contract expires on August 31, 2016. Contract dated August 4, 2016 (unnumbered) for 1231,90 square meters (monthly rent for 1,231.90 square meters: RUB 1,438,015.31, including VAT). The contract expires on July 31, 2017.

- OOO Inzhstroyservis for 35.3 square meters (Yekaterinburg office).
 Contract dated March 1, 2015. Monthly rent: RUB 30,800.00 (excluding VAT). The contract expires on January 31, 2016. Contract dated February 1, 2016. Monthly rent: RUB 30,800.00 (excluding VAT). The contract was anticipatorily terminated on September 30, 2016.
- OOO Inform-Future for 80.7 square meters (St. Petersburg office).
 Contract dated February 10, 2009 (unnumbered), Supplementary Agreement No. 4 dated January 1, 2016 (monthly rent in 2015: RUB 110902,78, including VAT). A contract with automatic renewal.
- OOO Inform-Future for 3.7 square meters (a utility room in St. Petersburg).
 Contract dated April 1, 2009 (unnumbered), Supplementary Agreement dated January 1, 2016 (monthly rent in 2016: RUB 3509,56, including VAT). A contract with automatic renewal.
- OOO UK Pyat morej for 32 square meters (Rostov-on-Don office).
 Contract No. 88 dated June 1, 2015: RUB 22,000.00, variable rental payment: from October 15, 2016 to April, 15, 2016 RUB 6 000.00 (excluding VAT), from April 16, 2016 to October 14, 2016 RUB 3 000.00. The contract validity is 11 month, expires on April 30, 2016.
 Prolongation due to supplementary agreement № 1 dated April 30, 2016, contract had been prolongated to March 31, 2017.
- ZAO Santens Service for 506.50 square meters (warehouse)
 Contract No. CA-03-01/14 dated January 14, 2014 (monthly rent: RUB 313,703.00, including VAT).
 A contract with a automatic renewal. Contract had been terminated on January 1, 2016.
 Contract No. CC-CA-03/14 dated February 1, 2016 for 568, 2 square meters (monthly rent: RUB 345073,30 including VAT). Valid for 11 month.
- ZAO SPTB for 29.3 square meters (Samara office).

Contract No. 21 dated January 17, 2014 (monthly rent: RUB 14,650.00, including VAT). Contract expiration date: not set.

- Market Style OOO for 31 square meters (Omsk office)
 Sublease Contract dated November 1, 2015 (unnumbered) (monthly rent: RUB 15,345.00). The contract expires on September 30, 2016. Sublease Contract dated October 1, 2016 (unnumbered) (monthly rent: RUB 15,345.00). The contract expires on September 30, 2017
- Individual entrepreneur V.A. Kataeva for 40 square meters (Krasnoyarsk office).
 Lease Contract dated December 19, 2015 (monthly rent: RUB 40 000.00). The contract expires on November 19, 2015. Lease Contract dated November 20, 2015 (monthly rent: RUB 40,000.00). The contract expires on October 20, 2017.
- TD VDNKh: (a utility room in Moscow)
 Contract No. 1102/15/618/1 dated December 28, 2015 (monthly rent: RUB 62239,30). The contract expires on November 30, 2016.

Sublease Contract No. 1600/16/618/1 dated December 8, 2016 (monthly rent: RUB 72217,32). The contract expires on October 31, 2017.

6.3. Additional information about the goods rejection procedure.

Goods that are subject to write-off and destruction are identified according to the following criteria: - expiration of shelf life;

- non-compliance with regulatory requirements;

- loss of marketability, etc.

automatic renewal clause.

The Company has entered into contracts for destruction of rejected goods with the following companies: OOO National Ecological Company: contract for pharmaceutical waste collection and disposal services No. N77-140/13 dated June 6, 2013 (License No. 076/00115 issued on March 22, 2013) with an

6.4. Information about the Company's expenses on wages, vacation pay and payment of bonuses to employees.

Structure of the accrued amounts in favor of the Company's employees in 2016:

Subdivision	2016, RUB'00 0	2016, %	2015, RUB'00 0	2015, %
Head Office (Moscow)	292 858	46,37%	226 027	59,20%
Standalone subdivision in St. Petersburg for the North-West and Volga Region	52 165	8,26%	38 010	10,53%
Standalone subdivision in Rostov-on-Don	84 855	13,43%	73 984	12,58%
Standalone subdivision in Yekaterinburg	46 733	7,40%	39 726	5,91%
Standalone subdivision in Krasnoyarsk	51 958	8,23%	43 721	3,58%
Standalone subdivision in Omsk	35 911	5,69%	26 108	1,91%

Standalone subdivision in Samara	64 443	10,20%	48 240	5,33%
Standalone subdivision Warehouse for wholesaling medical				
products in Istra District	2 679	0,42%	2 896	0,96%
Total	631 602	100%	498 711	100%

As at the end of 2016, the liabilities for payment of wages were discharged in full.

6.5. Information about the Company's deferred expenses on vacation pay and bonus payments to employees

The employees' accrued and unused vacations as at December 31, 2016, including insurance contributions, made up RUB 40 797 thousand; bonuses based on 2016 results, including insurance contributions, were RUB 40 223 thousand.

In 2017 the Company plans to accrue and pay the following amounts (short-term remuneration) to the key management personnel: labor remuneration in the amount of RUB 71 949 thousand, paid annual leaves in the amount of RUB 6 356 thousand; annual bounties amounted to RUB 4 625 thousand Long-term payments to key management personnel are not planned.

6.6. Notes to the Balance Sheet

6.6.1. The receivables recorded in the balance sheet line 1230 are short-term and amount to RUB 2 172 551 thousand. There are no long-term receivables. When preparing the balance sheet, the Company additionally discloses receivables relating to settlements with accountable persons and other settlements with employees; for comparison purposes, the balance sheet shows settlements as at December 31, 2015 and December 31, 2016.

6.6.2 Breakdown of accounts receivable (line 1230), RUB'000

Туре	2016	2015
Settlements on advances issued	116 704	26 274
Settlements with buyers and customers	1 899 300	1 572 431
Settlements with the budget (PIT)	514	473
Settlements with the budget (VAT)	-	
Settlements with the budget (advance income taxes)	73 404	44 675
Other taxes and levies		
Payments to extra-budgetary funds	3 645	4 862
Settlements with accountable persons	6 064	11 317
Settlements with employees on loans issued	9 159	5 805
Insurance settlements	7107	
Settlements of claims	37	3
Settlements with other debtors	63 724	46 516
TOTAL	2 172 551	1 712 356

6.7. Notes to the Profit and Loss Statement

6.7.1. Information on the expenses on ordinary activities.

The expenses on ordinary activities (production cost and business expenses) reported in the Profit and Loss Statement for 2016 amount to RUB 4 450 475 thousand. The cost of goods sold is RUB 3 065 092 thousand. Business expenses amount to RUB 1 385 383 thousand.

6.8. Notes to the Statement of Cash Flows

6.8.1. Other proceeds from operating activities (line 4119), RUB'000

	2016	2015
Value added tax (balance)	-	
Refund of taxes and levies from the budget	39 852	57 969
Refunds from customs authorities		5 829
Insurance indemnity	2 081	798
Other refunds	8552	3 538
TOTAL	50 485	68 134

6.8.2. Other payments within operating activities (line 4129), RUB'000

	2016	2015
Customs payments	101 492	110 977
Payment of taxes and contributions (other than		
income tax and VAT)	130 255	103 661
Payment for insurance	36 282	33 694
Advances to employees	44 464	38 045
Interest-free loans to employees	11 085	. 9 576
Payment of bonuses and return of goods by		
buyers	379	2 364
Value added tax (balance)	70 661	
Other payments	146 732	42 629
TOTAL	540 978	340 946

In 2016 the Company applied the method of accounting for customs payments to report cash flows: payment of VAT to the customs is shown as a separate item of cash flows and reduces the VAT balance in the Statement of Cash Flows, which is recorded within other payments in line 4129.

6.9. Other data

6.9.1. Inspections by the Social Insurance Fund.

- June 16, 2016: The Company got the Solution from Inspectorate of the Federal Tax Service № 17 of Moscow about the field tax audit № 19-25/1-91 dated June 16, 2016 for all taxes and fees, the audited period is from January 1, 2013 to December 31, 2015
- June 16, 2016: The Company got the Solution from IFTS № 17 of Moscow about the suspension of the field tax audit № 19-25/ПР-91 from June 30, 2016

- December 26, 2016: The Company got the Solution from IFTS № 17 of Moscow about resumption of the field tax audit № 19-25/вз-193 from December 26, 2016
- February 15, 2017: The Company was issued the Reference from IFTS № 17 of Moscow about the completion of the field tax audit №19-25/C-976 from February 15, 2017.

6.9.2. Events after the balance sheet date.

There were no events after the balance sheet date that could have a material impact on the presentation of the accounting statements in accordance with PBU 7/98.

The Company registered an increase in the amount of the authorized capital in 2016.

6.9.3. Provisions, contingent assets and liabilities

In accordance with PBU 8/2010, the Company made the following provisions for future expenses as at December 31, 2015:

- for payment of annual bonuses to employees in the amount of RUB 40 223 thousand;

- the payment of quarterly bonuses to employees in the amount of RUB 10 305 thousand;
- for future vacation payments in the amount of RUB 40 797 thousand;
- for returned goods in the amount of RUB 640 thousand;
- for imprest cash in the amount of RUB 6 041 thousand;
- for fuel and lubricants in the amount of RUB 2 487 thousand
- for other expenses in the amount of RUB расходы 61 354 thousand;

- for future expenses on bonuses to buyers for 2016 in the amount of RUB 166 139 thousand. The estimated liability for payment of bonuses to buyers was based on monetary valuation by the Company's management.

The Company has no contingent assets and liabilities.

In accordance with PBU 8/2010, the Company made the following provisions for future expenses as at December 31, 2015:

- for payment of annual bonuses to employees in the amount of RUB 30 715 thousand;
- for payment of quarterly bonuses to employees in the amount of RUB 14 794 thousand;
- for future vacation payments in the amount of RUB 30 130 thousand;
- for returned goods in the amount of RUB 366 thousand;

- for imprest cash in the amount of RUB 11 275 thousand;

- for other expenses in the amount of RUB 14 271 thousand;

- for future expenses on bonuses to buyers for 2015 in the amount of RUB 125 914 thousand. The estimated liability for payment of bonuses to buyers was based on monetary valuation by the Company's management.

The Company has no contingent assets and liabilities.

6.9.4. Related party transactions

U

The volume of transactions with related parties during the reporting period was as follows:

Related parties	Type of relation	Type of transactions	Applied pricing methods for each type of transactions	Volume of transactions in 2016	Volume of transactions in 2015
SUN	Other related	Purchase of	According to	RUB	RUB
PHARMACE	party(Parent	goods	the agreement	2 146 616	1 082 521
UTICAL	company of the	0	(market price)	thousand	thousand
INDUSTRIE	SUN			lioubuild	
S LTD (India)	PHARMACEU				
	TICAL				
	INDUSTRIES				
	LTD (India)				
	group)				
SUN	Other related	Receipt of a	According to	-	
PHARMACE	party (Parent	bonus for	the agreement		
UTICAL	company of the	purchasing			
INDUSTRIE	SUN	volume			
S LTD (India)	PHARMACEU				
	TICAL				
	INDUSTRIES			(à	
	LTD (India)				
	group)				
SUN	Other related	Compensatio	According to	_	RUB 4 458
PHARMACE	party(Parent	n for	the agreement		thousand
UTICAL	company of the	discount			
INDUSTRIE	SUN	given to the			
S LTD (India)	PHARMACEU	buyer			
	TICAL				
	INDUSTRIES				
	LTD (India)				
Ranbaxy	group) Other related	Durch and C			······································
Therapy		Purchase of	According to	RUB 896 850	RUB 894 400
Therapy	party (the company of the	goods	the agreement	thousand	thousand
	SUN	1	(market price)		
	PHARMACEU				
	TICAL				
	INDUSTRIES				
	LTD				
Ranbaxy	Other related	Receipt of a	According to		RUB 37 973
Therapy	party (the	bonus for	the agreement	-	
1.5	company of the	purchasing	the agreement		thousand
	SUN	volume			
	PHARMACEU				
	TICAL				
	INDUSTRIES				
	LTD				
Representativ	Other related	Purchase of	According to	RUB 275	RUB 7 593
e Office	party(the	fixed assets	the agreement	thousand	thousand
of Ranbaxy	Representatve		(market price)	arouounu	anousanu

Laboratories	Office of the				
Ltd.	SUN				
	PHARMACEU				
	TICAL				
	INDUSTRIES				
	LTD in Russia				
Representativ	Other related	Agency	According to	RUB 1 514	
e Office	party(the	contract	the agreement	thousand	
Of SUN	Representatve				
PHARMACE	Office of the				
UTICAL	SUN				
INDUSTRIE	PHARMACEU				
S LTD	TICAL				
	INDUSTRIES				
	LTD				
Representativ	Other related	Purchase of	According to	-	RUB 6 211
e Office	party(the	fixed assets	the agreement		thousand
of Ranbaxy	Representatve		(market price)		
Laboratories	Office of the				
Ltd.	SUN				
	PHARMACEU				
	TICAL				
	INDUSTRIES				
	LTD				
Ranbaxy	Principal	Repayment	According to	-	-
(Netherlands)	shareholder (99	of a long-	the set-off		
B.V.	percent of	term loan	agreement		
	stocks)		U		
Ranbaxy	Principal	Repayment			-
(Netherlands)	shareholder (99	of a short-			
B.V.	percent of	term loan			
	stocks)				
Ranbaxy	Principal	Accrual of	3M Libor +	USD 233	USD 203
(Netherlands)	shareholder (99	interest	150 bp p.a.	thousand	thousand
B.V.	percent of	under the	1 1 1		
	stocks)	short-term			
	,	loan			
		agreement			
		<u>v</u>			

L

Accounts receivable and payable to related parties of the Company as at December 31, 2015 were as follows:

in RUB'000

Related party	Type of relation	Amount of accounts receivable (payable) 2016	Amount of accounts receivable (payable) 2015
SUN PHARMACEUTICAL INDUSTRIES LTD (India)	Other related party(Parent company of the SUN PHARMACE	(1 502 589)	(1 075 666)

Laboratories Ltd.	Representatve Office of the SUN PHARMACEUTI CAL INDUSTRIES LTD in Russia)			
Sun Pharmaceutical Industries Ltd.	Other related party (the company of the SUN PHARMACEUTI CAL INDUSTRIES LTD (India) group)	Payment for fixed assets	RUB 1 789 thousand	RUB 279 thousand
Ranbaxy (Netherlands) B.V.	Principal shareholder (99 percent of stocks)	Payment of interest under the loan agreement	RUB 5 790 thousand	USD 6 606 thousand

In 2016, the following amounts were accrued in favor of key management personnel: labor remuneration in the amount of RUB - 60 685 thousand; paid annual leaves in the amount of RUB 2 900 thousand; rewards (bonuses) at year-end 2015 in the amount of RUB 6 437 thousand; other bonuses in the amount of RUB 18 329 thousand; and compensatory payments in the amount of RUB 1 055 thousand. In 2016, the Company provided short-term interest-free loans to management personnel in the amount of RUB 3 228 thousand. No long-term payments to key management personnel were made in 2016.

In 2015, the following amounts were accrued in favor of key management personnel: labor remuneration in the amount of RUB 22 965 thousand; paid annual leaves in the amount of RUB 1 206 thousand; rewards (bonuses) at year-end 2014 in the amount of RUB 3 836 thousand; other bonuses in the amount of RUB 9 213 thousand; and compensatory payments in the amount of RUB 277 thousand. In 2015, the Company provided short-term interest-free loans to management personnel in the amount of RUB 2 069 thousand. No long-term payments to key management personnel were made in 2015.

6.10. Information about the risks of business activity

6.10.1 General information about potential major risks of business activity.

The Company's activities are subject to various risks that may affect the achievement of set objectives. For the purposes of management of potential risks, the Company has implemented and develops a risk-based approach to business activities aimed at ensuring that the Company's management makes the most effective and efficient management decisions under uncertainty and identifying opportunities for achievement of the Company's objectives.

The most significant risks that could affect the Company's activities are grouped as follows:

- credit risks;
- liquidity risks;

- currency risks;
- legal risks.

6.10.2 Disclosure of information about credit risks.

The Company's credit risk is mainly concentrated in its trade and financial activities, and other accounts receivable.

Management is making every possible effort to minimize the Company's risk exposure. In particular, the creditworthiness of customers is assessed on the basis of the contractors' financial statements, which is a prerequisite for establishing credit limits under contracts for supply of goods. Management believes that there are no significant losses for which no provision for impairment related to these and other receivables was made as at December 31, 2016.

In order to reduce the risk of impairment of receivables from commercial organizations, the Company implements a number of procedures. Credit risk is determined by summarizing the probability and the possible impact of events that affect the customers' ability to meet their obligations. Credit rating is assigned to a customer at the beginning of cooperation and is then periodically reassessed on the basis of its credit history. As part of the credit risk management policy, the Company carries out preventive procedures, which include, but are not limited to, advance payments, requirement of a collateral, bank guarantees, letters of credit, and third party guarantees. To collect overdue receivables, the Company performs a number of actions starting from notification, suspension of the supply of goods, offsetting, and applying to courts.

As at December 31, 2016, the receivables secured by guarantees and sureties were as follows:

Buyer	Debt amount, rubles	Collateral amount	Guarantor / Surety
		rubles	
BSS LLC	51 626 834	80 000 000	VTB Bank OAO, branch in St. Petersburg
Grand Capital FC OOO	145 744 972	149 000 000	RaiffeisenBank, OJC
GPD	45 968 346	55 000 000	RaiffeisenBank, OJC
Katren NPK AO	436 423 690	800 000 000	OAO Katren (Russia)

Total	1 517 605 561	2 654 000 000	
000			
Farmpespektiva	58 310 558	60 000 000	RaiffeisenBank, OJC
Rosta ZAO	97 770 778	140 000 000	Uralsib Bank, PJSC
Pulse FC OOO.	296 843 494	650 000 000	OAO Sberbank of Russia
ProfitMed CJSC	69 921 647	70 000 000	OAO Sberbank of Russia
Protek TsV ZAO	314 995 239	650 000 000	OAO Sberbank of Russia

6.10.3 Disclosure of information about liquidity risks.

The Company monitors the risk of liquidity shortage at the stage of developing a cash flow budget and reviewing its implementation. The Company aims to maintain a balance between the provision of money and flexibility through the use of loans granted by the parent company. The cash flow budget takes into account the timing of cash inflows and outflows from the Company's operations. Decisions to invest available funds or raise external funding are adopted based on the projected cash flows. Through implementation of the liquidity risk management policy the Company ensures the availability of sufficient cash to meet liabilities when due.

6.10.4 Disclosure of information about currency risks.

In 2016, the Company had payables denominated in the loan currency and incurred foreign currency liabilities related to payment of interest on loans, due to which the Company is exposed to currency risk. These transactions are denominated in US dollars. Due to the sharp devaluation of the ruble during 2016, the Company incurred significant foreign exchange losses totaling RUB 87 772 thousand.

In order to reduce currency risk, the Company has switched to contracts with suppliers of goods providing for payments in rubles. With respect to monetary assets and liabilities denominated in foreign currencies, the Company's policy is aimed at maintaining the net position at risk within reasonable limits by purchasing and selling foreign currency at spot rates when necessary to address short-term imbalances.

Existence and movement of liabilities denominated in foreign currencies:

	Liabilities denominated in US dollars (USD'000)	Liabilities denominated in Euros (EUR'000)
Balance as at December 31,		
2015	6 973	none
New liabilities	233	none

Repaid	(88)	none
Balance as at December 31,		
2016	7 118	none

Official foreign currency exchange rates set by the Central Bank of the Russian Federation as at the balance sheet date were as follows:

	Exchange rate as at December 31, 2016	Exchange rate as at December 31, 2015
US dollar (USD)	60,6569	72,8827

After the balance sheet date, the exchange rate of the ruble appreciated by 4,44 percent against the US dollar and was 57, 9627 rubles for one US dollar at the date of signing these accounting statements.

6.10.5 Disclosure of information about other risks.

At present, the Company's major legal risks are related to changes in the tax legislation, legal regulations, and amendments to bylaws.

Currently, Russia has a number of taxes imposed at the federal, regional, and local levels. These taxes include the value added tax, the corporate income tax, the property tax, various insurance contributions (for mandatory pension insurance, mandatory social insurance, compulsory medical insurance), and other taxes.

The current tax legislation is subject to frequent changes. In addition, the interpretation of certain provisions of tax legislation can be changed by the judiciary. This results in a large number of disputes between tax authorities and taxpayers. These disputes are mainly resolved in courts. In addition, compliance with tax and other laws (for example, customs and currency laws) is subject to examination by various government authorities entitled to impose fines and penalties.

In accordance with applicable laws, tax authorities may audit the company's activities for the three years preceding the year of audit. The fact that the company's activities for a certain period have been audited by tax authorities does not mean that the company's tax liabilities for that period will not be audited in the future: tax authorities have the right to conduct a repeated tax audit by decision of a higher level tax authority or in case the taxpayer files revised tax declarations stating a lesser amount of tax than that declared previously.

The tax risks resulting from all these facts considerably exceed those that are customary for companies in countries with a better developed tax system. Management believes that the relevant provisions of legislation have been interpreted correctly and that the probability of maintaining the status of the Company in the context of tax, currency and customs legislation as at December 31, 2016 is high. *6.11. Summary.*

According to the results of its activities in 2016, the Company earned a profit of RUB 211 943 thousand. In 2016, sales increased by 37,61percent, while the share of cost in sales increased by 0,26

percent, which amounted to 61,35 percent in 2016 vs. 61,61 percent in 2015 and the share of business expenses increased insignificantly by 0,7 percent (27,73 percent in 2016 vs 27,53 percent in 2015).

There was a slight increased of other income by 35,72 percent in 2016, while other expenses also increased by 13,60 percent.

As a result of the Company's investment activities, namely, placement of funds in bank deposits, the Company made a profit of RUB 16 255 thousand, loaning, that gave a profit amounted to RUB 7 136 thousand in 2016.

CEO

_____/ Artur Valiev /

March 29, 2017

to the Accounting (Financial) Statements (RUB'000) Annex to the Notes

1. Intangible assets and of research, development and technological works (R&D) 1.1. Existence and movements of intangible assets

Form 0710005 p.1

2

.

1

du----

in the second

			ा 				Char	Changes over the period	eriod		-	At the end	At the end of reporting
			At the beginni	At the beginning of the vear		Dier	Dienneal						
ltem	Code	Period			_	2	nosal			Heval	Hevaluation		
			Historical cost	Accumulated amortization and impairment loss	Additions	Historical cost	Accumulated depreciation and impairment loss	Accrued amortization	Impairment loss	Historical cost	Historical Accumulated Historical cost amortization cost	Historical cost	Accumulated amortization and impairment
Total intangible assets	5100	2016	4 834	(3516)	7 361								1030
	5110	2015	A 92A				10	(1 446)	•	•	•	12 195	(4 963)
ncluding:		202	+ 004			8	2	(1 611)	•	-	•	4 834	(3 516)
other intangible assets	5101	2016	4 587	(3 420)	6 691			(1 950)					
	5111	2015	4 587								-	11 278	(4 773)
Exclusive copyright to	5102	2016	247		023			(679.1)	-			4 587	(3 420)
computer programs,	5112	2015	247		0/0			(64)	<u>,</u>		-	917	(190)
							·	(82)	<u>·</u>			247	(96)

- 1411of into 4 1.2 Historical

		1.2. HIStorical cost of intangible assets developed in-house	ntangible assets deve	eloned in-house
ltem	Code	As at 31 December 2016	As at 31 December 2016	As at 31 December 2011
Total	5120			٢.
including:				'
	5121	,	i	

Contraction of the second

1.3. Fully amortized intangible assets	Code As at 31 December 2016 As at 31 December 2015 As at 31 December 2014	5130 4 -		5131 4.	
	Item	Total	including:		

	ĺ
ults	
D res	
of R&	
ents c	
Veme	
and mo	
ice ai	l
cister	
4. E	ŀ
-	
	ŀ

					The subscript and movements of how results	C I COUILO			i	
			At the beginni	At the beginning of the year		Changes over the period	er the period		At the end o	At the end of the period
						Disposals	osals			
	900-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0	Period	Historical cost	Expensed portion	Additions	Historical cost	Expensed portion	Expensed portion for the period	Historical cost	Expensed
Total R&D	5140	2016	3					Ī		Ī
	5150	2015	,							
including:										
	5141	2016	4					`		
	5151	2015	-							

1.5. R&	D in prog	1.5. R&D in progress and n	ot formalized and a	ot formalized and acquisitions of intapplible assets in progress	idible assets in nro	<u>Ö</u> race	
					Changes over the period	000 5	
Item	Code	Period	At the beginning of the				At the end of the nariod
			year	Costs for the period	Costs written off as unproductive	Recognized as intangible assets or R&D	
Costs of R&D in progress - total	5160	2016					
	5170	2015					
including:							
	5161	2016					
	5171	2015					
Acquisitions of intangible assets in progress	5180	2016		7 361		11 004)	
	5190	2015				(1.361)	
including:							
Sketch "Ketanov Kids, Active"	5181	2016		1 070		1020 11	
	5191	2015				(0101)	
Videoclip "Through the clouds"	5182	2016		5.621		1E CO41	
	5192	2015				(170 C)	
Intellectual property "Registration and approval of	5183	2016		670			
purchase orders"	5193	2015	3			(0/9)	

T

Form 0710005 p.4

9

2.1. Existence and movements of fixed assets

					visitine and movements of myed assets	CIILS UL IIAC	su assels					
							Changes over the period	ir the period			At the end i	At the end of the period
tem.	epo C		At the beginnir	ng of the year		Disposal	osal		Reval	Revaluation		
	anoo	Leriod	Historical	Accumulated	Additions	Historical	Accumulated	Accrued	Historical	Accumulated	Historical	Accimilated
			cost	depreciation		cost	depreciation	depreciation	cost	depreciation	cost	depreciation
I otal fixed assets (excluding income-	5200	2016	82 321	(50 307)	4 128	(8 478)	8 340	(16 879)	3	9	120 24	10001
pearing investments into tangible	5210	2015	73 020	(36 694)	16 966	(7 665)	7 167	(010 00)			1/6//	(28 846)
including:							2	100 / 001		•	125.28	(50 307)
Vehicles	5201	2016	69 986	(45 714)	963	(7 340)	7 202	(13 488)				(100 OL)
	5211	2015	69 295	(33 928)	8 356	(7 GEE)	7 1 5 7				00 00	(100 ZC)
Other fixed assets	5202	2016	284	(220)	2000	(nnn))	/01 /	(506 81)	'	'	69 986	(45 714)
	5212	2015	200	(677)				- (22)		7	284	(221)
Office anninment	5000	0107	007	(177)	48			- (8)			284	(000)
	2203	2016	11 377	(4 127)	3 165	(1 138)	1 138	(3 236) -			12 402	
	5213	2015	2 815	(2 442)	8 562 -			(1 202)			004 01	(077 0)
Machinery and equipment (except	5204	2016	404	(153)	722						11 377	(4 127)
office equipment)	5214	2015	VUV					- (80)			404	(232)
Production and organizational stock	5205	2016	1010	(0)				- (08)			404	(153)
	5215	2015	020	(+0)				(53) -			270	(137)
Total income-bearing investments into	5220	2016	212	(10)		<u>·</u>		(53)			270	(84)
tancihla assets	CCEV	2010						-				
	5230	2015										
incluaing:												
	5221	2016	<u>.</u>									
	5231	2015										
						_		<u>.</u>	-			

Code
5240
5250
5241 2016
-
\downarrow
2016
╡
5255 2016 5255 2015
5246 20
5247 2016
\downarrow
5258 2016 5258 2015
201
2016
102
201
201
201
2013
2016
2015
2016
2015
2016
2015
2016
2015
2016
2015

[

1 and

1

Law 1

	49 -	1	491-	2		77		49 -	-	49 -		49 -		49.	2	40.	, 7	101	- 07	- 01			P7	20	, 7	48	P	48 -	2	48 -	2	48.	2 7	48	2	48	- -	01	40	av	2	48.	2	. 94	,	48	2	e e	+0		48 -	7	48	-	OV
																																					,							e			,					c		-	
	49		49		40	f		D 4		49		49		49		49		48		48	2	48		48		48		48		48		48		48		48	2	48	2	48		48		48		48		4R		ΔA	ţ		48		48.
																																																							-
2016 -	2015-	2016 -	2015 -	2016-	2015 -	2016	2015	2010		- CIU2	2016 -	2015	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016-	2015 -	2016 -	2015 -	2016 -	2015	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015	2016.	2010	2013	2016	20151
Laptop HP ProBook 640 Core i5-4210M with a case	anton UD BroBook 640 Caro in 10404 - 44	Lapich nr ridouok 040 Core 15-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core 15-4210M with a case		anton UB Broback 640 Care in 194001 Cu	Lapido ITE FIODUOK 040 COTE 10-4210M WITH & CASE		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core I5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		

48 -		481-		48 -	-	48 -		48 -	2	48 -		0	40	40	-	48 -		Q	10			48 -	2	48 -	2	48 -		48 -		59 -		258 -		244 -		246 -		244 -	-	244 -		244 -		258 -		258 -		244 -		49 -		215-	2	209 -
																																Ñ		5		5		2		2		57		ŝ		5		54		4		21		06
48		48		48		48		48		48		48	2	48		48	2	48	2	48		48		48		48		48		6		8		4		9		4		4		4		8				+		6				
4		4	-	4		4		4		4		P		4		4				P		4		4		4		4		59		258	2	244		246		244		244		244		258		258	1	244		49		215		209
2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016	2015	2016 -	2015	2016 -	2015	2016 -	2015 -	2016	2015 -	2016	2015 -	2016-	2015			- 9102	- GIUS	2016 -	2015 -	2016		2016		2016-	2015-	2016 -	2015 -	2016 -	2015
	Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Laptop HP ProBook 640 Core i5-4210M with a case		Venicie: KIA Rio 1.6 MT Z94CB41BAER168446		VENICIE: NIA HIO 1.0 MI 2940641BADH154034	Mohine: Mie Die 4 of htt Touron unter and and	VENICIE: KIA HID 1.6 MI 294CB41BADH153961	Vehicle: VIA Die 4 6 Mrt 30400 400 400 400 400		Vehicle: KIA Bin 1.6 MT 704/0B11BADD1E3001		Vehicle: KIA Din 1 8 MT 704CB118 ADD150810		Vahicle: KIA Pio 1 6 MT 701/0919 ADD150000		Vahicle: KIA Bio 1 6 NT 701CD11D ADD1-000		Vehicle: KIA Bin 1 6 MT 704/08/18/00152024		Vahirla: Onal Astra Li 1/8 AT		Vokiale: Bass. # Sanda Vali Bassa in: 10000	VERICIE: HERAUI SANGERO X/LESHB2HDH665001		Vehicle: Renault Sandero X7LBSRB2HDH652303	

Vehicle: Renault Sandero X7LBSRB2HCH557211 2016 Vehicle: Renault Sandero X7LBSRB2HCH557193 2016 Vehicle: Renault Sandero X7LBSRB2HCH557193 2016 Vehicle: Renault Sandero X7LBSRB2HCH553226 2016 Vehicle: Renault Sandero X7LBSRB2HCH553229 2016 Vehicle: Renault Sandero X7LBSRB2HCH553219 2016 Vehicle: Renault Sandero X7LBSRB2HCH553218 2016 Vehicle: Renault Sandero X7LBSRB2HCH4553218 2016 Vehicle: Renault Sandero X7LBSRB2HBH415566 2016 Vehicle: Renault Sandero X7LBSRB2HBH415566 2016 Vehicle: Renault Sandero X7LBSRB2HBH415566 2016 <	67 - 67 - 67 - 67 - 67 - 67 - 45 - 45 - 45 - 45 - 45 - 45 - 45		67	
HCH557211 HCH557210 HCH557193 HCH553220 HCH553220 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH5556 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH42556 HBH415565 HBH415565 HBH415565			94 G	
HCH557210 HCH553220 HCH553220 HCH553220 HCH553219 HCH553219 HCH553219 HCH553219 HCH553218 HCH553218 HCH553218 HCH553218 HCH353882 HCH353882 HCH353882 HCH353880 HCH353880 HBH423979 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH42365 HBH42565 HBH42565 HBH42565 HBH42565 HBH42565 HBH42565 HBH42565 HBH42565 HBH42565 HBH415565 HBH415565 HBH415565 HBH415565	67 - 67 - 67 - 67 - 45 - 45 - 45 - 45 - 45		67	
HCH557210 HCH557210 HCH557226 HCH553226 HCH553226 HCH553219 HCH553219 HCH553219 HCH552407 HCH552407 HCH4553219 HCH4552407 HCH423982 HCH423982 HCH423980 HCH423979 HCH423979 HCH423979 HCH423979 HCH423979 HCH423979 HCH423979 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH423978 HCH42365 HCH423978 HCH42365 HCH423978 HCH42365 HCH423978 HCH42365 HCH425 HCH42365 HCH42365 HCH42365				
HCH557193 HCH553226 HCH553226 HCH553220 HCH553220 HCH553219 HCH553219 HCH553214 HCH553214 HCH5524114 HCH45532 HBH415566 HBH415566 HBH415566 HBH423979 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565	67 - 67 - 45 - 45 - 45 - 45 - 45 - 45		- /0	
HCH557193 HCH553226 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH553218 HCH45532 HBH415566 HBH415566 HBH423979 HBH415565 HBH423978 HBH423978 HBH423978 HBH423978 HBH42556 HBH42556 HBH425565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565			ľ	
HCH553226 HCH553226 HCH553219 HCH553219 HCH553219 HCH553218 HCH553218 HCH553218 HCH553218 HCH353882 HCH4233882 HBH42566 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH42365 HBH42365 HBH421582 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565			- /9	
HCH553226 HCH553226 HCH553219 HCH553219 HCH553218 HCH553218 HCH552407 HCH4552407 HCH423982 HBH415566 HBH415566 HBH423979 HBH415565 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565				
HCH553220 HCH553219 HCH553219 HCH553218 HCH553218 HCH552414 HCH552407 HCH4552407 HCH42538 HBH415566 HBH415566 HBH423979 HBH415565 HBH415	45 - 45 - 45		- /9	
HCH553220 HCH553218 HCH553218 HCH553218 HCH552407 HCH552407 HCH352407 HCH4552407 HCH423982 HBH415566 HBH415566 HBH415565 HBH423978 HBH423978 HBH423978 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565				
HCH553219 HCH553219 HCH553218 HCH553218 HCH5532414 HCH352407 HCH423980 HBH415566 HBH423979 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH42365 HBH421582 HBH415565 HBH415565 HBH415565 HBH415565	- 45		45 -	
HCH553219 HCH553218 HCH552407 HCH552407 HCH4552407 HCH4552407 HBH415566 HBH415566 HBH423980 HBH423979 HBH415565 HBH423978 HBH423978 HBH423978 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565				
HCH553219 HCH553218 HCH553218 HCH552414 HCH552407 HCH552407 HCH4553862 HBH45632 HBH415566 HBH415566 HBH423979 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565 HBH415565	- 45		45 -	
HCH553218 HCH552414 HCH552407 HCH4552407 HBH415566 HBH415566 HBH423999 HBH415566 HBH423978 HBH423978 HBH423978 HBH423978 HBH423978 HBH42365 HBH421582 HBH415565 HBH415565	45		2	
HCH553218 HCH553218 HCH552407 HCH4552407 HCH423982 HBH415566 HBH415566 HBH415566 HBH415566 HBH415566 HBH415565 HBH41565 HBH41565 HBH41565 HBH41565 HBH415565			46	
HCH552414 HCH552407 HCH552407 HCH4552407 HBH415566 HBH415566 HBH415566 HBH423979 HBH423978 HBH423978 HBH423978 HBH42565 HBH415565 HBH415565 HBH415565			-	
HCH552414 HCH552407 HCH4552407 HBH415566 HBH415566 HBH415566 HBH423979 HBH423978 HBH423978 HBH423978 HBH423978 HBH42365 HBH42565 HBH421582 HBH415565 HBH415565			-	
Tichesiza14 HCH552407 HCH4552407 HBH445632 HBH415566 HBH423980 HBH415566 HBH423979 HBH415565 HBH417198 HBH415565 HBH415565 HBH415565 HBH415565	45		45	
HCH552407 HCH4552407 HBH415566 HBH415566 HBH415566 HBH415566 HBH423979 HBH423978 HBH423978 HBH423978 HBH42556 HBH415565 HBH415565	•			
HCH552407 HCH423982 HBH4456532 HBH415566 HBH423980 HBH415566 HBH423979 HBH423978 HBH423978 HBH423978 HBH415165 HBH415565 HBH415565 HBH415565	45			
HCH423982 HBH445632 HBH415566 HBH415566 HBH423980 HBH41556 HBH423979 HBH415198 HBH415198 HBH415565 HBH415565 HBH415565			P P	
HCH423982 HBH415566 HBH415566 HBH415566 HBH423979 HBH423978 HBH423978 HBH423978 HBH42555 HBH415565 HBH415565 HBH415565		6		
HBH415632 HBH415566 HBH4239800 HBH423999 HBH423978 HBH423978 HBH423978 HBH421582 HBH415565 HBH415565	45		45 -	
HBH445632 HBH415566 HBH423980 HBH423979 HBH423978 HBH423978 HBH423978 HBH417198 HBH415565 HBH415565 HBH415565			Ŷ	
HBH415566 HBH415566 HBH415566 HBH423979 HBH423978 HBH423978 HBH421582 HBH415565 HBH415565	16		16 -	
HBH415566 HBH4239800 HBH423979 HBH423978 HBH423978 HBH421582 HBH421582 HBH415565 HBH415565				
HBH415566 HBH423980 HBH423980 HBH423979 HBH423978 HBH423978 HBH415565 HBH415565 HBH415565	16		at	
HBH4239800 HBH415556 HBH423979 HBH423978 HBH417198 HBH417198 HBH415565 HBH415565 HBH415565			2	
HBH423980 HBH415556 HBH423979 HBH423978 HBH42198 HBH421582 HBH415565 HBH415565				
HBH415556 HBH423979 HBH423978 HBH423978 HBH417198 HBH415565 HBH415565 HBH415565	2		16 -	
HBH415556 HBH423979 HBH423978 HBH417198 HBH417198 HBH415565 HBH415565 HBH415555	•		-	
HBH415556 HBH423979 HBH423978 HBH42798 HBH421582 HBH415565 HBH415565	16		16	
HBH423979 				
HBH423979 HBH423978 HBH417198 HBH421582 HBH415565 HBH415565 HBH415555				
	0		16 -	
1BH423978 1BH417198 1BH4151582 1BH415565 1BH415555	-		1	
181423978 181417198 181421582 181415565 181415565	16		16 -	
	-			
	- 16		16	
			2	
	16			
			-	
			1	
	2		16 -	
1BH415555				
	16		16 -	
			V	
_	16		16	
Vehicle: Renault Sandero X7LBSRB2HBH370165 2016 2016 -				
	4			
Vehicle: Renault Sandero X7LBSRB2HBH369467 20161- 20161-	2		- 0	
		•		_
	16	-	16 -	

[

				14																																													
	- H	2	10		16.		26		29-		27		- 62		23		25 -		25-	10		45	2	45-		209 -		176 -		169 -			43 -		- 68		431 -	431 -		28		20		41-		215 -	·		
	16		9		0		9		6		2																																						
	-		F		7		26		29		27		23		23		25		ŝ	35	5	45		45		209		176		201	44		43		89	+04	2	431		8		64	11	41	246	212	171		
2016	2015-	2016 -	2015 -	2016-	2015 -	2016 -	2015 -	2016	2015 -	2016 -	2015 -	2016-	2015 -	2016 -	2015 -	2016-	2015 -	2016 -	2019 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016-		2015 -	2016-	2015 -	2016 -	2015 -	2016 -	2015-	2015-	2016 -	2015 -	2016 -	2015 -	2016 -	- 5102	2015	2016 -	2015 -	2016-	2015 -	2016 -	204
Vehicle: Renault Sandero X7LBSRB2HBH415563		Vehicle: Renault Sandero X7LBSRB2HBH415559		Venicie: Henault Sandero X7LBSRB2HBH415557		VEIIICIE: N/A HIO 1.4 MI KNADH411AA6588840	Vehicle: VIA Bio 1.1 MT VAIADU221 2.2000000			Venicie: KIA Hio 1.4 MJ KNADH411AA6588828		VENICIE: KIA HIO 1.4 MI KNADH411A46588819		VENICIE: KIA HIO 1.4 MT KNADH411AA6588812	Wohiele: KIA Bie 4,4 and issues (1997) 2000	VENICIE: NA HID 1.4 MI KNAUH411A46588809	Vehicle: KIA Bin 1.4 MT KNADU4114 A 6550007		Vehicle: Chevrolet Cruze XUFJA696JC3020459		Vehicle: Renault Sandero X7LBSRB2HCH552408		Venicle: Henault Sandero X7LBSRB2HCH553222	Vehicle: Bonsutt Soudors VII BCBBol In Lincond		Vehicle Renault SR X711 SBAAHOH240120		Vehicle: Renault SR X7LLSRAAH9H249121		TV-set LED Philips PFL		Low-current cable system (LAN)	Piran Catal at Onco 1410 Conco 1520 1	Usco Catalyst 2960 WS-C2960-48TC-L + adapters_f ininternintable notion control	Commutator Cisco Catalvet± 2 modules 1		Commutator Cisco Catalyst+ 2 modules 2		Server Prollant DL380R07 E5620+ HDD 1			Storage / Archive for server 1		Storage / Archive for server 2		Vehicle: Renault SR X7LLSRAAH9H234998		Vehicle: Renault logan X7LLSRB1HCH564728	

D

	385 -		- 9/1	- 270		250.	- 000	163		547 -	- 110	235		450 -		547 -		159 -		159 -		206 -		- 99		88 -		- 88		- 88		66]-		117 -		147 -	-	120 -		- 90		- 90	- 33	- 00		- 90		- 00	-	66 -	•	59 -	
	CAE	176		279		259		163		547		235		159		547		159		159	-	206		99		88		88	_	88		66)T	130	150		3	99	3	66		99	3	ee l	3		8	1	- AC	_
													•		•		-		•		•					_	-		_	_	- -			-										-									*
2015	2016 -	2015	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	- 20102	2015 -	- 9102	- 0102	2016	2016 -	2015	2016	2015	2013 -	2016 -	2013 -	2015	2015	2015 -	2016 -	2015 -	2016 -	2015 -	2016-	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	2015 -	2016 -	-12124
	Vehicle: Renault SR X7LLSRAAH9H249130		Vehicle: Renault SR X7LLSRB1HCH564722		Venicie: Henault logan X/LLSHB1HCH557260		Vernicie: Henauli SH X/LLSHABH9H245632	I later	DIMINIER UPURADIE POWER SOURCE APC SMAR-UPS SRT		CININER UPIADIE POWER SOURCE APC SMART-UPS RT		Domain up and bower source APC Smart-UPS HT	Juduva 230V	DM 100001/1/000000		3000VA 230V	Uninterruptable power source APC Smart Lips PT	3000VA 230V	Vehicle: RENAULT SR X711 SRB1HAH3331506		Vehicle: Renault Sandero X7LBSRB2HBH415553		Vehicle: Renault Sandero X7LBSRB2HCH552411		Vehicle: Renault Sandero X7LBSRB2HCH557209		Vehicle: Renault Sandero X7LBSRB2HCH552413		Vehicle: Renault Sandero X7LBSRB2HBH423985		Vehicle: Renault Sandero X7LBSRB2HDH652307		Vehicle: KIA Rio Qb Z94CB41BADR154011		Vehicle: Chevrolet Cruze XUFJA696JC3027015		Vehicle: Renault Sandero X7LBSRB2HBH423981		Vehicle: Renault Sandero X7LBSRB2HBH415554		Venicie: Henault Sandero X7LBSRB2HBH415567		Venicie: Henault Sandero X7LBSHB2HBH423983		venicie: Henault Sandero X7LBSRB2HBH370164		Venicle: Henault Sandero X7LBSRB2HBH415562		Laptop HP ProBook 640 Core i5-4210M with a case		Vehicle: Renault Sandero X7LBSRB2HCH552409	

Vehicle: Renault Sandero X7LBSRB2HBH415564	2016	- 9				
	2015			39		
Vehicle: Renault Sandero X7LBSRB2HBH423984	2016			2		- 90
	201			66		
Vehicle: KIA Rio Z94CB41BAER167005	2016					- 99
	201		147			2
Laptop HP ProBook 640 Core i5-4210M with a case	2016				147	7 -
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016	·		R	29	- 6
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016		RC	2	59	- 6
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016		R		59	9-
	2015					1
Laptop HP ProBook 640 Core i5-4210M with a case	2016				59	9-
	2015				~	-
Laptop HP ProBook 640 Core i5-4210M with a case	2016		R	2	59	9
	2015				*	•
Laptop HP ProBook 640 Core i5-4210M with a case	2013		28		59	- 0
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016		ñ		59	9-
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016		ñ		59	
	2015		ED.			
-aptop HP ProBook 640 Core i5-4210M with a case	2016		5		28	
	2015		20		Cu	,
Laptop HP Probook 640 Core i5-4210M with a case	2016				ő	
	2015		29			-
Laprop HP Probook 640 Core I5-4210M with a case	2016				8C	
Lanton HD BroBook 640 Corr is 10101	2015		59		50	
	2016					
Lapton HP ProBook 640 Core is 4210M with 2 2220	2015		59		29	
	2016				*) 	
Laptop HP ProBook 640 Core i5-4210M with a case	2012		20		59	
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2015		59		59	
	2015					
Laptop HP ProBook 640 Core i5-4210M with a case	2016		20		59	
	2015		59			
Laptop HP ProBook 640 Core i5-4210M with a case	2016		8		RC	
Disk storado array HD Charles 111	2015		29		60	
A siviaye allay nr Slarageworks P2000 SAS g3	2016					
Vehicle: Renault Menano VE187400412202110	2015		153		153	
	2016					
Vehicle: Nissan Tiida 3N1BCAC11111 446389	2015		172		172	
	2010					
Vehicle: Renault SR X7LLSRB1HAH331573			130		130	
	2010					
Vehicle: Renault Sandero X7LBSRB2HCH557212	2012		88		88	
	2015					
Vehicle: Chevrolet Cruze XUFJA696JC3030117	2016		88		88	
	2015		35			
Xerox WorkXCentre 5230A	2016-		3		35	
•		2				

	2015 -	110	-1101-1	
Xerox WorkXCentre 5330	2016 -	ŝ		
	2015 -	118	118	
Xerox WorkXCentre 5230A	2016 -			
	2015 -	110		
Laptop HP ProBook 640 Core i5-4210M with a case	2016 -			
	2015 -	R51	054	
Laptop HP EliteBook 820 Core i5-4210M with a doc-	2016 -			
station	2015 -	5	č	
Vehicle: KIA YD (Cerato, Forte)	2016]-		- ī	
XWEFX411AE0001439	2015 -	236	236	

3

-

2.3. Changes in the cost of fixed assets resulting from further construction, additional equipment, reconstruction or partial liquidation

ailidinha	int, reconstruction		
Item	Code	in 2016	in 2016
otal increase in the cost of fixed assets as a result of further construction,	5260		C107 III
cinding:			
FORD Mondeo X9FDXXEEBD9K47683	5261		
tal decrease in the cost of fixed assets as a result of partial liquidation	5270		
Studing:			
	5271		

ĺ

[

Com

State of the state

The second se

3.1. Existence and movements of financial investu

			3.1. Exist	tence and n	novements	3.1. Existence and movements of financial investments	ul investme	nts			
							Changes over the period	r the period		At the and ,	At the end of the period
tem		[At the beginnin	ning of the year		Disposed	Disposed of (repaid)				
	2000	Dorrad	Historical cost	Accumulated adjustments	Additions	Historical cost	Historical Accumulated cost adjustments	Accrual of interest (Including to bring cost	In current market value (impairment	Historical cost	Accumulated
Long-term - total	5301	2016						io par value)	loss)		
,	5311	2015				,	·				
including:		207									
	5302	2016	.	. 1							
	5312	2015								-	•
Short-term - total	5305	2016	425 000		3 662 333	2 675 000					
	5315	2015	235 000		Τ					412 333	
including:					Т					425 000	
Loans issued	5306	2016			137 333						
	5316	2015								137 333	
Bank deposits	5306	2016	425 000		3 525 000	3 675 000					-
	5316	2015	235 000		Т					275 000	
Total financial investments	5300	2016	425 000		Т			-		425 000	
	5310	2015	235,000			-3 0/0 000		-		412 333	
		2: 22					•			425 000	

[

0

and the second se

3.2. Other utilization of financial investments	5320		ransferred to third parties (except sale) - total 5325		5326	n or infrancial investments 5329 5329	
	rieuged inancial investments - total		Investments transferred to third partie	interacting.	Other utilization of E	Outer unitzation of financial investmen	

				ורב מווח ווור	T.I. EAISIGHUG AND INUVERIENIS OF INVENTIOLIES						
					Changes over the period	e period					
	8	9	At the beginni	At the beginning of the year		Disposed of				At the end of the year	of the year
Item	Code	Period	cost	provision for impairment	additions and costs	cost	provision for impairment	impairment losses	inventory turnover between groups (types)	cost	provision for impairment
Total inventories	5400	2016	719 034	(3 862)	4 696 058	(4 501 100)	227 616	(286 023)	×	913 991	(62 269)
	5420	2015	472 405	(16 014)	3 530 288	(3 283 659)	83 087	(91 418)	×	719 034	(3 862)
including:											
Raw materials, supplies and other similar assets	5401	2016	31	•	43 040	(43 053)			•	18	,
	5421	2015	96	•	24 786	(24 850)	•	ľ	•	31	
Finished products	5402	2016	•	•	-	•	•	•	•		•
	5422	2015	-	•		'	'			·	ľ
Goods for resale	5403	2016	715 013	(3 862)	3 265 114	(3 072 664)	227 616	(286 023)	3 134 402	907 463	(62 269)
	5423	2015	468 460	(16 014)	2 505 770	(2 259 217)	83 087	(91 418)	2 590 176	715 013	(3 862)
Goods and finished products shipped	5404	2016	•	•	1	-	י א				-
	5424	2015	•	•	•	•			,	1	•
Work in progress costs	5405	2016	•	•			Ī	2	*	5	ŕ
	5425	2015	1	•						•	
Other inventories and costs	5406	2016	3 989	1	1 387 903	(1 385 383)	·	8	a.	6 509	·
	5426	2015	3 850		999 732	(399 592)	•	•		3 989	
Deferred expenses (for analytical accounting Items recorded within inventories)	5407	2016	•		•	8	*	÷	ž		'
	5427	2015	•	,	1		31		,		
	5408	2016	20	,		•		'		100	•
	5428	2015		•			•	•	2	8	

4. Inventories 4.1. Existence and movements of inventories

0

1

Q

0

Q

8

1

	4.2. Inver	4.2. Inventory pledged		
Item	Code	As at 31 December 2016	As at 31 December 2016 As at 31 December 2015 As at 31 December 2014	As at 31 December 2014
Total inventory unpaid as at the reporting date	5440	¢.		
including:				
	5441	1	•	•
Total inventory pledged as collateral under contracts	5445		•	
Including:				
	5446	1	1	1

ļ

5

Pert.

1

5. Receivables and payables 5.1. Existence and movements of receivables and payables

							Chan	Changes over the period	ariod				At the and a	6 the next d
		0	At the beginning of the year	ng of the year	adc	additions			disposals					
liem	Code	Period			arising from									
			accounted for under	provision for doubtful	business transactions	interest, penalties and other	renaid	charged against	reversal of	reclassificatio n from long-	reclassificatio reclassificatio n from long- n from n from	reclassificatio n from	accounted	provision for
			contracts	debts	(transaction amount	charges due		financial result	provision	term to short- term	receivables to payables	payables to receivables	for under contracts	doubtful debts
Total long-term receivables	5501	2016			outstandino)	2								
	5521	2015						7		1				
including:							Ī							ň
Settlements with buyers and	5502	2016	<u> </u>	<u>.</u>										
customers	5522	2015												12
Advances made	5503	2016							2					0 <u>7</u>
	5523	2015												
Other	5504	2016												
	5524	2015												
	5505	2016												
	5525	2015												
Total short-term receivables	5510	2016	1 759 467	(47 111)	7 022 270		-6 599 696		(E0 1E0)		J.C.			
	5530	2015	1 434 841	(38 939)	5 058 629		4 734 004		100 1001		8	2	2 182 093	(9 543)
including:									(160 /0)				1 759 467	(47 111)
Settlements with buyers and	5511	2016	1 618 495	(46 063)	5 537 593		(5 248 293)		(60.160)				101 100 1	
costorners	5531	2015	1 339 896	(37 891)	3 997 972		(3 719 373)		(37 801)				1 307 / 34	(G64 8)
Advances made	5512	2016	27 330	(1 048)	437 427		(347 004)		1 200 101				1 618 495	(46 063)
	5532	2015	15 080	(1 048)	240 330		(228.080)						11/ /53	(1 048)
Other	5513	2016	113 642 -		1 047 251		(1 004 399)						27 330	(1 048)
	5533	2015	79 865 -		820 327		(786 550)	Ī			8	18	156 546 -	
	5514	2016										•	113 642 -	
Cottomonte ou contraction	5534	2015												
Settlements on social insurance	5515	2016												
	5535	2015												
Other settlements with	5516	2016												
personnei	5536	2015							Ť					
Settlements with accountable	5517	2016							Ť					
persons	5537	2015												
	5500	2016	1 759 467	(47 111)	7 022 270	-	-6599696427		(E0 1E0)	>	,			
	5520	2015	1 434 841	(38 939)	5 058 629		4734003709	8	(37 801)		<>	<	2 182 093	(9 543)
									1.22.22	-	<	<	104 601	(111/4)

	5.2.	5.2. Overdue receivables	eivables				
		As at 31 December 2016	ember 2016	As at 31 Dec	As at 31 December 2015	As at 31 December 2014	ember 2014
ltem	Code	accounted for under contracts	book value	accounted for under contracts	book value	Ēø	book value
Total	5540			T		140	
including:							
Settlements with buyers and customers	5541			÷			
Settlements with buyers and customers (on advance navments							
prepayments)	5542						
Other	5543						
	5544						

				Снал	Changes over reporting period						
Item	Code	Period	Balance at the			Bbi0	BbiObiJIO				
			beginning of the year	arising from business transactions (transaction amount outstanding	interest, penalties and other charges due	repaid	Written-off to P&L	transfer from long- to short- term debt	reclassification from receivable to payables	reclassific ation from payables to	Balance at the end of reporting period
Total long-term payables	5551	2016								receivable	
	5571	2015									
	5552 5572	2016 2015								_	
	2010	5012									
-	0003 5573	2016								T	
	5554	2015									
_	5574	2015									
	5555	2016									
	5575	2015									
Total short-term payables	5560	2016	2 176 367	5 365 954	16 715	(5 107 BED)					
	5580	2015	1 638 762	4 268 018	13 800	1000 101 01			•	•	2 451 166
				2		1000 444 01	·		•	•	2 176 367
settlements with buyers and customers	5561	2016	1 627 497	3 733 629	•	(3 392 490)	1				1 000 000
	5581	2015	1 049 596	2 806 392		(2 228 492)					1 500 030
	5562	2016	375	121 134		(121 251)					1 02/ 49/
	5582	2015	452	152 375		(152 452)		ľ			270
	5563	2016	9 163	514 874	•	(499 653)				-	C/C
	5583	2015	10514	381 437	2	-382 789					C0 450
	5584	2016									201
	5565	2016	508.213		46.746	145 4 2041					
L _	5585	2015	387 289	247 110	CI / 01	(151 401)		·	-	-	431 788
	5566	2016	31 119	036 307	12 000	(140 083)		·	·	-	508 213
1	5586	2015	32 511	670 005		(940 344)	'		•	-	26 101
settlements with founders on contributions to	5567	2016		1222		(10+ 000)	•			•	31 119
	5587	2015								┨	
	5550	2016	2 176 367	5 365 954	16 715	(5 107 869)		>	+	+	0 154 400
	5570	2015	1 638 762	4 268 018	13 890	(3 744 303)		</td <td>< ></td> <td>< ;</td> <td>2 401 100</td>	< >	< ;	2 401 100

1

1

[]

N N

100 300

- and

6. Produc	6. Production costs		
ltem	Code	2016	2015
Material evolution			2012
	5610	39 842	22 994
Labor costs	5620	539 437	427 168
Social security contributions	5630	124.310	OB FEE
Depreciation	5640	10.075	
Other coete		676 01	22 392
	5650	665 988	428 611
i otal	5660	1 387 002	1000
Change in balances (increase [-1): of work in programs finished	3	206 100 1	10/ 666
goods, etc.	5670	(2 520)	(001)
Change in balances (decrease [+]): of work in progress, finished		(5.020)	(801)
aoods. etc.			
	- 000C	-	
I utal expenses from ordinary activities	5600	1 385 382	999 592

[

E

and the second

and a

2

[

1

-

-

	7.	7. Estimated liabilities	ties			
ltem	Code	Balance at the beginning of the	Recognized	Reversed	Written off as	Balance at the end
Estimated liabilities - total		year			excess	of the period
including.	5700	227 466	463 718	(360 137)	/3 0E1/	
				1.2. 2221	100 01	32/ 98/
Provision for fuel and lubricants	5701					
Provision for returned anode			0 392	(3 905)	•	2 487
	20/9	366	482		(000)	
Frovision for vacation pay	5703				(208)	640
Provision for navment of annual beauses to small	3	30130	49 618	(38 951)]-		40.707
Out the section of annual politices to employees	5704	30 715	58 911	(007 07)		
	5705			(004 64)		40 223
Bonuses to huvers		14 2/1	49 936	15	(2 853)	61 251
Provision for some of the second se	5706	51 435	87 236	(79.484)		
revision for payment of quarterly bonuses to employees	5707	762 71	NOAN NI	1.2.2.1		/81 FC
Provision for imprest amounts	1700		- (20+ +)		1	10 305
Volume discernate to him	90/C	11 276	(5 235)			
voluting discounts to puyers	5709	027 72	100 000			b 041
		01	100 022	- (188 394)		106 952

8	8. Security	8. Security for obligations		
ltem	Code	As at 31 December 2016	As at 31 December 2016 As at 31 December 2015 As at 31 December 2014	As at 31 December 2014
Received - total	5800	3 774 776	1 630 000	1 625 000
including:				
	5801			
Given - total	5810			
including:				
	5811			

-

-

- And

1

.....

12

and and

		9. Gover	9. Government aid			
Item		Code	20	2016	20	2015
Budgetary funds received - total		5900				2
including:						
for current expenditures		5901		ī		
for investments in non-current assets		5905				
			At the beginning of	Received during	At the beginning of Received during Repaid during the At the end of the	At the end of the
-			the year	the year	year	vear
Budgetary loans - total	in 2016	5910	•			
	in 2015	5920				
including:						
	in 20156	5911		-		
	in 2015	5921				